Compound Name:  CLS-TA, triamcinolone acetonide injectable suspension 
Protocol Number:  CLS100 1-301 
IND Number:  115683  
Study ID: [REMOVED]  
Protocol Title  PEACHTREE: A Phase 3, Randomiz ed, Ma sked, 
Controlled C linical T rial to Study the Safety and Efficacy  
of Triamcinolone Acetonide Injectable Suspension (CLS -
TA) for t he Treatment of Subjects with Macular Edema 
associated with Non -Infectious Uve itis 
Sponsor:  Clearside Biomedical, Inc.  
900 North Point Parkway, Suite 200  
Alpharetta, GA 30005  
Issue D ate: 
Protocol Amendment 1 Date:  
Protocol Amendment 2 Date:  
Protocol Amendment 3 Date:  25 August 2015  
24 November 2015  
22 July 2016  
12 April 2017  
 
CLS1001-301 Clinical Protocol Clearside Biomedical, Inc. 
Version 4.0 12 Ap
ril 2017 Page 1 of 65 
CONFIDENTIAL  Clinical Protocol CLS1001-301 
Project: 
Compound Number/Name: 
Protocol Number: IND Number:  
Phase: 
Protocol Title: 
Sponsor: 
Medical Monitor: 
Original Protocol Issue Date: 
Amendment #3 Issue Date: Amendment #2 Issue Date: Amendment #1 Issue Date:1001 
CLS-TA, triamcinolone acetonide injectable suspension 
CLS1001-301 
115683  
3 
PEACHTREE: A Phase 3, Randomiz Ed, M Asked, 
Controlled Clinical Trial to Study the Safety and Efficacy 
of Triamcinolone Acetonide Injectable Suspension (CLS-
TA) for t He TReatment of Subject s with Macu lar Edema 
associated w
ith Non-Infectious Uv Eitis 
Clearside 
Biomedical, Inc. 
900 North Point Parkway, Suite 200 
Alpharetta, GA  30005 
Chiltern, Inc.  
David Hoelscher, MD
 
Senior Medical Officer 
David.Hoelscher@chiltern.com 
Direct:    +1 
423 990 0288 
Mobile:   +1 512 694 8829 
Fax:        +1 423 968 3567 
 25AUG2015 
12APR2017 
22JUL2016 
 24NOV2015 
________________________________________________ ___12 April 2017 ______ 
Jennifer Kissner, Ph.D.            Date 
Vice President, Clinical Development 
Clearside Biomedical, Inc.  
CONFIDENTIAL 
This protocol contains confidentia l information about a product provided by Clearside Biomedical, Inc.  
This information is provided for the exclusive use of  the Investigators participating in this study.  Any 
and all confidential information c ontained herein may not be disclosed to any other person or party 
without the prior written consent of Clearside Biomedical, Inc.  

CLS1001- 301 Clinical Protocol Clearside Biomedical, Inc.  
Version 4.0 12 April 2017  Page 2 of 65 
CONFIDENTIAL  Clinical Protocol C LS1001-301 
Investigator Signature Page 
I agree:  
•To assume responsibility for the proper conduct of the study at this site.
•To conduct the study in compliance with this protocol, any future amendments, and with  
any other study conduct procedures provided by the Sponsor, C learside Biomedical, Inc.
(Clearside).
•Not to implement any deviations from or changes to the protocol without agreement from 
the Sponsor and prior review and written approval from the Institutional Review Board /
Ethics Committee (IRB/IE C), except where n ecessary to eliminate a n immediat e hazard to 
the subjects, or for administrative aspects of the study (where permitted  by all applicable 
regulatory
 requirements).
•That I am thoroughly familiar with the appropriate use 
of the investigational drug(s), as 
described in this protocol and any other information provided by the Sponsor including,  
but not 
limited to the following: the current investigator’s brochure or equivalent  
document provided by Clearside and approved product label, if applicable.
•That I am aware o f, and will comply with, “good clinical practices” ( GCP) and all 
applicable r egulatory requirements.
•To ensure that all persons assisting me with the study are adequately informed about the
 
investigational drug(s) and of their study-related duties and functions as 
described in the 
protocol.
•To periodic on-site monitoring of the case report f orms (CRFs) and source documents by  
Clearside or designee and to on-site inspection of CRFs and source documents by 
appropriate 
regulatory authorities, including but not limited to the US Food and Drug 
Administration (FDA), local governing regulatory bodies, and IRB/IE C inspectors.
•That I have been informed that certain regulatory authorities require the Sponsor to obtain 
and supply details about the investigator’s ownership interest in the Sponsor or study 
drug, and more generally about his/her financial ties with the Sponsor.  C learside will use 
and disclose the information solely for the purpose of complying with regulatory  
requirements. 
Hence I:  
•Agree
 to supply Clearside with any information regarding ownership interest and
financial ties (including those of my spouse and dependent children);
•Agree to promptly update this information if any relevant changes occur during the
course of the study and for 1 year following completion of the study; and
•Agree that Clearside may disclose this information about such ownership interests and
financial ties to regulatory authorities.
Investigator Name (Print)  Investigator  Signature Date  
CLS1001- 301 Clinical Protocol  Clearside Biomedical, Inc.  
Version 4.0 12 April 2017  Page 3 of 65 
CONFIDENTIAL  TABLE OF CONTENTS  
LIST OF ABBREVIATION S AND DEFINITIONS OF  TERMS  ..................................................8  
1. INTRODUCTION  ........................................................................................................9  
1.1. Disease Background  .....................................................................................................9  
1.2. Scientific Rationale  .......................................................................................................9  
1.3. Description of Investigational Product .......................................................................10  
1.4. Summary of Clinical Experience and Justification for Route of 
Administration and Dose Selection  ............................................................................11  
1.5. GCP C ompliance ........................................................................................................11  
1.6. Population to be Studied .............................................................................................12  
2. TRIAL OBJECTIVES AND PURPOSE  ....................................................................13  
2.1. Primary Objective  .......................................................................................................13  
2.2. Secondary Objective  ...................................................................................................13  
2.3. Additional Objectives  .................................................................................................13  
3. TRIAL DESIGN  .........................................................................................................14  
3.1. Endpoints ....................................................................................................................14  
3.1.1.  Primary  Endpoint ........................................................................................................14  
3.1.2.  Secondary Endpoint ....................................................................................................14  
3.1.3.  Additional Endpoints ..................................................................................................14  
3.1.4.  Safety Endpoints  .........................................................................................................14  
3.2. Description of Study and Duration of Participation ...................................................14  
3.2.1.  Description of Trial Design  ........................................................................................14  
3.2.2.  Trial Treatments  ..........................................................................................................15  
4. SELECTION AND WITHDRAWAL OF SUBJECTS  ..............................................16  
4.1. Inclusion Criteria  ........................................................................................................16  
4.2. Exclusion Criteria  .......................................................................................................16  
4.2.1.  Ophthalmic Exclusion Criteria  ...................................................................................16  
4.2.2.  General Exclusion Criteria  .........................................................................................17  
4.3. Subject Discontinuation/Withdrawal from Clinical Study  .........................................18  
4.3.1.  Discontinuation of the Clinical Study .........................................................................18  
5. PROCEDURES  ..........................................................................................................19  
5.1. Visit Description  .........................................................................................................19  
5.1.1.  General Procedures  .....................................................................................................19  
CLS1001- 301 Clinical Protocol  Clearside Biomedical, Inc.  
Version 4.0 12 April 2017  Page 4 of 65 
CONFIDENTIAL  5.1.2.  Re-screening Procedures  ............................................................................................19  
5.1.3.  Visit 1 – Screening (Day -14 to -1) ............................................................................19  
5.1.4.  Visit 2 – Randomization/Treatment (Day 0)  ..............................................................20  
5.1.5.  Visit 3 – Week 4 Post Randomization Follow-Up (Day 28 ±5) .................................22  
5.1.6.  Visit 4 – Week 8 Post Randomization Follow-up Visit (Day 56 ±5) .........................22  
5.1.7.  Visit 5 – Week 12 – TREATMENT VISIT 2 (Day 84 ±5)  ........................................22  
5.1.8.  Visit 6 – Week 16 Post Randomization Follow-up Visit (Day 112 ±5) .....................24  
5.1.9.  Visit 7 – Week 20 Post Randomization Follow-up Visit (Day 140 ±5) .....................24  
5.1.10.  Visit 8 – Week 24 End of Study Visit (Day 168 ±5) or Early Termination 
Visit  .............................................................................................................................24  
5.1.11.  Unscheduled Visit .......................................................................................................25  
6. TREATMENT OF SUBJECTS ..................................................................................26  
6.1. Treatments to be Administered  ...................................................................................26  
6.1.1.  Study Eye Determination  ............................................................................................27  
6.1.2.  Treatment of the Fellow Eye (Non -Study Eye)  ..........................................................27  
6.2. Concomitant Medications ...........................................................................................27  
6.2.1.  Prohibited Medications ...............................................................................................27  
6.2.2.  Additional Treatment  ..................................................................................................28  
6.3. Treatment Compliance  ................................................................................................28  
6.4. Drug Accountability ...................................................................................................28  
6.5. Masking / Unmasking .................................................................................................29  
7. ASSESSMENTS OF EFFIC ACY  ..............................................................................31  
7.1. Best Corrected Visual Acuity (BCVA)  ......................................................................31  
7.2. Central Subfield Thickness as Measured by SD- OCT  ...............................................31  
7.3. Visual Function Questionnaire (VFQ-25) ..................................................................31  
7.4. EQ-5D .........................................................................................................................31  
7.5. Pharmacokinetics Assessments  ..................................................................................31  
8. ASSESSMENTS OF SAFET Y ..................................................................................32  
8.1. Intraocular Pressure ....................................................................................................32  
8.2. Slit-Lamp Biomicroscopy ...........................................................................................32  
8.2.1  Cataract Lens Grading  ................................................................................................32  
8.2.2  Anterior Chamber Cells  ..............................................................................................32  
8.2.3  Anterior Chamber Flare  ..............................................................................................33  
CLS1001- 301 Clinical Protocol  Clearside Biomedical, Inc.  
Version 4.0 12 April 2017  Page 5 of 65 
CONFIDENTIAL  8.3. Dilated Ophthalmoscopy ............................................................................................33  
8.3.1  Vitreous Haze  .............................................................................................................33  
8.4. Fluorescein Angiography  ............................................................................................34  
8.5. Fundus Photography ...................................................................................................34  
8.6. Review of Systems  .....................................................................................................34  
8.7. Clinical laboratory tests  ..............................................................................................34  
8.8. Vital signs  ...................................................................................................................35  
8.9. Evaluation of Adverse Events ....................................................................................35  
8.9.1.  Definitions  ..................................................................................................................36  
8.9.2.  Adverse Event Reporting Procedures .........................................................................38  
8.9.3.  Prompt Reporting of SAEs to the Sponsor .................................................................38  
8.9.4.  Pregnancy Reporting  ..................................................................................................39  
8.9.5.  Transmission of SAE Reports and Pregnancy Forms .................................................39  
8.9.6.  Regulatory Reporting Requirements for SAEs ...........................................................39  
8.9.7.  Follow-up of AEs and SAEs .......................................................................................40  
9. STATISTICAL CONSIDERATIONS  .......................................................................41  
9.1. Randomization ............................................................................................................41  
9.2. Deter mination of Sample Size and Level of Significance  ..........................................41  
9.3. Subject Disposition, Demographic and Baseline Characteristics ...............................41  
9.4. Analysis Populations ..................................................................................................41  
9.5. Analysis Methods .......................................................................................................42  
9.5.1.  Primary Efficacy Analysis  ..........................................................................................42  
9.5.2.  Secondary Efficacy Analysis  ......................................................................................42  
9.5.3.  Subgroup Analysis ......................................................................................................43  
9.5.4.  Pharmacokinetic Analysis  ..........................................................................................43  
9.5.5.  Safety Analysis  ...........................................................................................................43  
9.5.6.  Interim Analysis  ..........................................................................................................44  
9.5.7.  Extent of Exposure .....................................................................................................45  
9.5.8.  Procedure for Accounting for Missing, Unused, or Spurious Data ............................45  
9.5.9.  Multiplicity  .................................................................................................................45  
9.5.10.  Procedure for Reporting Deviations from the Statistical Analysis Plan  .....................45  
10. DIRECT ACCESS TO SOU RCE DATA/DOCUMENTS .........................................46  
10.1.  Investigator Training  ..................................................................................................46  
CLS1001- 301 Clinical Protocol  Clearside Biomedical, Inc.  
Version 4.0 12 April 2017  Page 6 of 65 
CONFIDENTIAL  10.2.  Monitoring ..................................................................................................................46  
10.3.  Audits ..........................................................................................................................46  
11. QUALITY CONTROL AND QUALITY ASSURANCE  .........................................47  
12. ETHICS  ......................................................................................................................48  
12.1.  Institutional Review Board/Ethics Committee  ...........................................................48  
12.2.  Unanticipated Problems and Notification to Sponsor and IRB/IEC ..........................48  
12.3.  Informed Consent Requirements ................................................................................49  
13. DATA HANDLING AND RECORD KEEPING  ......................................................50  
13.1.  Data Quality Control and Reporting ...........................................................................50  
13.1.1.  Source Documents ......................................................................................................50  
13.1.2.  Case Report Forms  .....................................................................................................50  
13.1.3.  Subject Tracking  .........................................................................................................50  
13.1.4.  Study Files  ..................................................................................................................50  
13.2.  Archiving of Data .......................................................................................................51  
13.3.  Records Retention  .......................................................................................................51  
14. FINANCING AND INSURANCE  .............................................................................52  
14.1.  Finance ........................................................................................................................52  
14.2.  Insurance .....................................................................................................................52  
15. PUBLICATION POLICY  ..........................................................................................53  
16. REFERENCES  ...........................................................................................................54  
17. APPENDICES  ............................................................................................................55  
APPENDIX A.  TIME AND EVENTS SCHE DULE ..................................................................56  
APPENDIX B.  SUMMARY OF CHANGES FOR AMENDMENTS  .......................................58  
 
CLS1001- 301 Clinical Protocol  Clearside Biomedical, Inc.  
Version 4.0 12 April 2017  Page 7 of 65 
CONFIDENTIAL  LIST OF TABLES  
Table 1:  Anterior Chamber Cell Grading Scale  ........................................................................33  
Table 2:  Anterior Chamber Flare Grading Scale  ......................................................................33  
Table 3:  Scale for Determining Degree of Vitreous Haze  ........................................................34  
Table 4:  Clinical Laboratory Analytes to be Tested  .................................................................35  
Table 5:  Causality Definitions  ..................................................................................................38  
 
LIST OF FIGURES  
Figure  1: Study Overview  ..........................................................................................................15  
 
 
CLS1001- 301 Clinical Protocol  Clearside Biomedical, Inc.  
Version 4.0 12 April 2017  Page 8 of 65 
CONFIDENTIAL  LIST OF ABBREVIATION S AND DEFINITIONS OF TERMS 
AE  Adverse Event  
BCVA  Best Corrected Visual Acuity  
CRF  Case Report Form  
CST Central Subfield Thickness 
EDC  Electronic Data Capture  
ETDRS  Early Treatment of Diabetic Retinopathy Study  
EQ-5D European Quality of Life 5-Dimensions 
FA Fluorescein Angiography 
GCP  Good Clinical Practice  
ICH International Conference on Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use  
IEC Institutional Ethics Committee  
IOP Intraocular Pressure 
IRB Institutional Review Board  
IND Investigational New Drug  
IRT Interactive Response Technology 
ITT Intent- to-Treat  
IVT Intravitreal  
MedDRA  Medical Dictionary for Regulatory Activities  
NSAID  Non-Steroidal Anti- Inflammatory Drug  
OCT Optical Coherence Tomography  
PK Pharmacokinetics  
PP Per Protocol 
SAE  Serious Adverse E vent 
SCS Suprachoroidal S pace 
SD-OCT  Spectral -Domain Optical Coherence Tomography 
TA Triamcinolone Acetonide 
TEAEs  Treatment Emergent Adverse Events  
VEGF  Vascular Endothelial Growth Factor  
VFQ  Visual Function Questionnaire 
CLS1001- 301 Clinical Protocol  Clearside Biomedical, Inc.  
Version 4.0 12 April 2017  Page 9 of 65 
CONFIDENTIAL  1. INTRODUCTION 
1.1. Disease Background  
Clearside is developing drugs to treat  unmet or underserved blinding eye diseases. Part of this 
drug development strategy involves a novel approach  using suprachoroidal administration  to 
deliver  drugs in high bioavailability via this local treatment paradigm  to precisely access specific 
areas of the eye . Clearside’s  development al efforts have f ocused on uveitis where there is need 
for a locally administered medically beneficial therapy, which has the potential to provide a more 
encompassing and  differentiating efficacious  and safe treatment for patients . Based upon results 
from preclinical data in animal models of uveitis and from early clinical data in uveitis patients , 
the suprachoroidal approach for the treatment of uveitis is being developed to fulfill this unmet 
need .  
Uveitis is a general term used to describe a set of ocular inflammatory dis eases. The whole eye 
can be affected in uveitis or the inflammation may dominate in specific locations of the eye. 
Uveitis is therefore classified by anatomic location within the eye as being anterior -, 
intermediate -, posterior- or pan- uveitis  (Nussenblatt 1985) according to the primary site of 
inflammation. Each of these categories, however, encompasses a number of conditions that can 
be characterized further along other dimensions. Uveitis can be described by temporal features 
based on the onset (sudden or insidious), the duration (limited or persistent) and the course (acute, recurrent or chronic); and according to its etiology, in terms of being infectious or 
noninfectious, with the latter subgroup comprising entities that are either autoimmune, traumatic, 
idiopathic, or masquerade conditions (neoplasti c or drug -induced disorders mimicking uveitis).  
Uveitis is the fifth most common cause of visual loss in the developed world (Goldstein 2009; 
Wood 2011; Miserocchi 2013). Significant vision loss can occur in up to 35% of children and adults, and uveitis accounts for 5% - 20% of legal blindness in both the United States and 
Europe, and perhaps as much as 25% of blindness in the developing world (Rothova 1996; Bodaghi 2001). 
There are a number of causes associated with this vision loss including cataract formation or 
progression, chorioretinal scarring, retinal detachment, and secondary glaucoma, but the 
dominant cause of vision loss within uveitis comes from chronic macular edema accounting for 
about one third of visual impairment or blindness (Wood, 2011; Dick, 1994; Karim, 2013). Approximately 30% of all uveitis patients and up to 60% of intermediate- and pan- uveitis 
patients experience macular edema (Lardenoye, 2006).  
Macular edema, the major cause of visual loss in uveitis, is defined as abnormal thickening of the macula associated with the accumulation of fluid in the outer plexiform and the inner nuclear 
layers of the retina, and occasionally the intracellular spaces as a result of the breakdown of the 
blood-retinal barrier (Dick, 1994; Cho, 2009).   
1.2. Scientific Rationale  
Uveitis is commonly treated with corticosteroids and other immunomodulatory agents; such 
treatments are either systemic or local. Systemic treatments are most commonly intravenous or 
oral whereas local treatments are either topical drops , intra- ocular or peri -ocular injections or 
implants . If the uveitis dominantly affects the anterior segment, topical steroid drops may be 
CLS1001- 301 Clinical Protocol  Clearside Biomedical, Inc.  
Version 4.0 12 April 2017  Page 10 of 65 
CONFIDENTIAL  effective therapy. In almost all other cases, steroids for initial treatment are given orally while 
non-steroidal immunosuppressive treatments are administered intravenously. Depending on the 
specific kind of uveitis both steroid and other immunosuppressive therapy may be used at the 
same time. Higher oral steroid doses, 60-80 mg /day, used for initial treatment are th en tapered to 
a maintenance dose of <10 mg/day for management of ongoing uveitis. Based both on the specific differential  diagnosis and on investigator preference, treatments in clinical practice tend 
to vary, although guidelines for the use of both steroids and other immunosuppressive agents are available (Jabs, 2000).  
The challenge with systemic, frequently oral , cortico steroid treatments for ophthalmic 
inflammatory conditions is that these treatments are often associated with adverse events (AEs) 
such as  peptic ulcerations, osteoporosis, necrosis of the hip, weight gain, muscle weakness, 
hyperglycemia, and systemic hypertension. All currently used modes of steroid administration for ophthalmic conditions, including local administrations , are associated with increases in 
intraocular pressure that could result in glaucoma, progression of glaucoma, and to both the formation and the progression of cataracts (Karim, 2013).  
Topical corticosteroids given as eye drops for anterior uveitis, have not shown that the y are 
capable of reducing complications of uveitis such as macular edema in a consistent manner. 
Since macular edema is the leading cause of sight threatening blindness in uveitis, methods other 
than topical drops are usually used when macular edema, or ot her local complications persist in 
uveitis. I ntravitreal injections of corticosteroids, or implantation of sustained corticosteroid 
delivery devices in or proximal to the vitreous can be used to administer therapeutic agents so 
that they are available to t he posterior segment, provide local therapy, and reduce macular edema 
and other local uveitic complications (Ghate, 2007).  While the intravitreal route of administration enables availability of the drug to the posterior segment, the procedure leads to significant exposure of the administered cortico steroid to anterior segment ocular structures. 
Similar issues plague periocular corticosteroid administration. Cataract  formation, elevated 
intraocular pressure that can lead to glaucoma and worsening of pre- existing glaucoma  are 
common adverse effects of  periocular and intraocular administration of corticosteroid treatments . 
The potential advantages of using suprachoroidal administration  to precisely  provide local 
corticosteroid therapy to the affected tissues of the eye are that it can result in robust efficacy 
based upon data from animal models and from Phase 1/2 clinical data and it has the potential for 
reducing the amount of drug dosed because of the high bioavailability of drug in the retina and choroid. Further, the unique distribution of drug following suprachoroidal administration confining it to the posterior segment and sparing anterior segment portions of the eye, along with 
the extremely low systemic steroid exposure to other organs in the body ca n provide 
differentiating efficacy along with the potential for improved safety.   
1.3. Description of Investigational Product  
CLS-TA, triamcinolone acetonide injectable suspension (CLS -TA), is a sterile , preservative- free, 
aqueous suspension formulated for administration into the eye.  The drug product is terminally 
sterilized and is intended for single use.  CLS-TA is supplied as a 40 mg/mL sterile suspension in a 2 mL/13 mm TopLyo® single use vial with a rubber stopper and an aluminum seal.   
CLS-TA must be stored under ambient temperature conditions at ca. 20° - 25° C (68° - 77° F); 
do not freeze. CLS-TA should be protected from light by storing in the carton provided. 
CLS1001- 301 Clinical Protocol Clearside Biomedical, Inc.  
Version 4.0 12 April 2017  Page 11 of 65 
CONFIDENTIAL  CLS-T A will be administered as a single injection of 4 mg in 10 0 microliters (µL). 
Additional information regarding CLS
-TA is available in th
e Investigator’s Brochure. 
1.4. Summary of Clinical Experience  and Justification for Route of 
Administration and Dose Selection  
TA ha s been safely and effectively us ed in hum an ocular therapeutics t o treat ocular conditi ons 
involving inflammation for over 50 years. The initial recommended dose of the TA formulation 
(Triesence®) approved by the FDA for ocular indications i s 4 mg in 100 µL.  
Clearside is de veloping CLS-TA, a proprietary T A formulation, f or the treat ment of non-
infectious  
uveitis b y administration  to the  SCS. T his therapy for uveitis is pa rt of Clearside’s  
paradigm of developing dr
ug treatments f or unmet or unde rserved blinding eye diseases where 
the pathologies dominantly originate or manifest in the choroid and the retina.  
The dose of CLS-TA, administered as a single s uprachoroidal injection, will be  4 mg in 100 µL. 
Clearside has one 
completed and one ongoing c linical stud y of up t o 4 mg T A administered 
suprachoroidall
y to subjects w ith non-infectious uveitis .  
The completed c linical study, CLS1001-101, was a Phase 1/2, open- label, s af ety a nd tolerability 
study in s ubjects w ith intermediate -, posterior-, or pan- non- infectious uve itis. E ach s ubject 
receiv ed a single suprachoroidal injection of 4 mg in 100 µL TA (T riesence ). Nine  (9) of the 11 
subject s ubjects i n the safety analysis s et (82%) completed t he 26 -week study. A ll subjects ha d at 
least one  AE, with a tot al of 37 AEs reporte d. One serious event (unrelated pul monary e mboli; 
SAE) oc curred. No d eath
s were reported.  
Approximately h alf of the reported AEs were ocular eve nts. No  significant  increases i n IOP were 
reported.  Nine
 ocular AEs, i
n four subjects , were consi dered possibly related to TA. The most 
commonly reported AE , eye pa in, w as reported in 5 subject s. There were n o serious adverse 
events ( SAEs) reported as related to the study drug. N o systemic AEs w ere report ed as related t o 
study drug. 
The ong oing 
clinical study, CLS1001-201, is a Phase 2, r andomized,  masked s afety and efficacy 
study in s ubjects w ith ma cular e dema associated w ith non-infectious  uveitis . Each s ubject will 
receiv
e a single suprachoroidal i njection  of CLS-TA, 4 mg in 100 µL or 0.8 mg in 100 µL . As of  
31JUL2015, 11 subjects have been enrolled into this study and 5 ha ve completed the study. A s of 
this date
, four
teen A
Es have been reported; 8 of the AEs in 4 subjects ar e ocular i n nature and  
none have been reporte d as s
erious.  
Additional information regarding clinical experience with T A administered to the SCS, i s 
available in 
the Investigator’s Brochure. 
1.5. GCP Compliance  
This clinical trial will be conducted in accordance with the principles of the Declaration of 
Helsinki, and in compliance with the International Conference on Harmonization (ICH) E6 Good 
Clinical Practice  (GCP ) guidelines and other applicable regulatory requirements. The 
Investigator and all clinical study staff will conduct the clinical study in compliance with the 
protocol. The Investigator will ensure that all personnel involved in the conduct of the study are 
CLS1001- 301 Clinical Protocol  Clearside Biomedical, Inc.  
Version 4.0 12 April 2017  Page 12 of 65 
CONFIDENTIAL  qualified to perform their assigned responsibilities through relevant education, training and 
experience.  
1.6. Population to be Studied  
The study population includes approximately 150 adult subjects to be enr olled at approximately 
60 study sites. To participate in the study, subjects must be 18 years or older with macular 
edema associated with  non- infectious uveitis  of any etiology , and from among those with 
anter ior-, intermediate -, posterior - or pan -uveitis . The expected duration of participation in the 
study is up to 27 weeks . The complete inclusion and exclusion cri teria are presented below in 
Section 4 . 
CLS1001- 301 Clinical Protocol  Clearside Biomedical, Inc.  
Version 4.0 12 April 2017  Page 13 of 65 
CONFIDENTIAL  2. TRIAL OBJECTIVES AND  PURPOSE  
The purpose of this study is to evaluate the safety and efficacy of suprachoroidally administered  
CLS-TA, triamcinolone acetonide injectable suspension, for the treatment of macular edema 
associated with  non-infectious uveitis.  
2.1. Primary O bjective 
The p rimary  objective of the study is to demonstrate the efficacy of  CLS -TA as shown by the 
change from baseline in BCVA in subjects with macula r edema associated with  non-infectious 
uveitis  
2.2. Secondary Objective 
• To determine mean change from baseline in central subfield thickness  
2.3. Additional Objectives 
• To determine systemic exposure to triamcinolone acetonide following suprachoroidal 
injection of CLS -TA 
• To determine the change from baseline  with respect to subject-reported outcomes 
 
CLS1001- 301 Clinical Protocol  Clearside Biomedical, Inc.  
Version 4.0 12 April 2017  Page 14 of 65 
CONFIDENTIAL  3. TRIAL DESIGN  
3.1. Endpoints  
3.1.1. Primary Endpoint  
The primary endpoint is the proportion of subjects with a change from baseline of ≥ 15 letter s in 
ETDRS BCVA  at Visit 8 (24 weeks), subsequent to supra choroidal injection s of CLS-TA or 
sham injection procedures, in subjects with macular edema associated with  non-infectious 
uveitis.  
3.1.2. Secondary Endpoint  
• Mean change from baseline in CST as measured by SD -OCT at 24 weeks (Visit 8)    
3.1.3. Additional  Endpoints  
• Triamcinolone acetonide blood concentrations prior to each dose (Visit 2 and 5), 4 
weeks following the first dose (Visit 3) and at 24 wee ks (Visit 8)  
• Change from base line in subject reported outcomes as measured by the Visual 
Function Questionnaire, VFQ -25 and the EQ-5D questionnaire at Visit 8 ( 24 weeks)   
3.1.4. Safety Endpoints  
• Incidence of treatment -emergent adverse events (TEAEs) and serious adverse events 
(SAEs), grouped by organ system, relatedness to study treatment and severity  
• Percentage of subj ects whose IOP increases  are > 10 mmHg  from their own baseline 
measurement at each  follow-up visit ( except Visit 2 & 5 [post-dose])  
• Percentage of subj ects whose IOP increases to a reading > 30 mmHg at each follow-
up visit (except Visit 2 & 5 [post-dose]) 
• Percentage of subjects who require 1 or more additional IOP lowering medications at any follow-up visit (except Visit 2 & 5 [post-dose]) 
3.2. Description of Study and Duration of Participation  
3.2.1. Description of Trial Design  
This is a Phase 3, randomized, masked, sham- controlled, multicenter study to assess the safety 
and efficacy of 4  mg of CLS -TA administered via suprachoroidal injection compared to a sham 
injection procedure in the treatment of subjects with macular edema associated with  non-
infectious uveitis.   
The study design includes 8 clinic visits over a maximum of 27 weeks .  Subject eligibility will be 
established at Visit 1 during the screening process (Day -14 to -1 ).  Eligible subjects will return 
to the clinic for Visit 2 , Randomization (Day 0).  Qualified subjects will be randomized to 
receive two  unilateral  suprachoroidal injection s of CLS -TA administered to the study eye or two 
unilateral sham injection procedures administered to the study eye , approximately 12 weeks 
apart  (Visit 2 and Visit 5) .  Follow- up visits will be  conducted monthly up to 24 weeks (Visit 8) . 
CLS1001- 301 Clinical Protocol Clearside Biomedical, Inc.  
Version 4.0 12 April 2017  Page 15 of 65 
CONFIDENTIAL  Subjec ts will ha ve a final eva luation conducted 24  weeks (Visit 8)  following ini tial 
randomization. Approximately 25% of the subjects will be included in a pharmacokinetic 
evaluation for the study.  Figure 1 below depicts the study overview: 
Figure  1: Study Overview  
3.2.2. Trial Treatments  
Subjects
 will be randomized at Visit 2  to Active or Control arms in  a 3:2 ratio. 
Subjects randomized to the A ctive arm  will re ceive unilateral  suprachoroidal inj ection s of 4 mg 
(100 µL of 40 mg/mL) CLS -TA at Day 0 ( Visit 2) and Week 12 ( Visit 5).   
Subjects randomized to the C ontrol arm will receive unilateral sham injection procedures in 
which no drug or vehicle will be administered, at Day 0 ( Visit 2) and Week 12 ( Visit 5). The 
sham injection procedure will mimic the active injection in order to maintain the subject’s 
masking.   

CLS1001- 301 Clinical Protocol  Clearside Biomedical, Inc.  
Version 4.0 12 April 2017  Page 16 of 65 
CONFIDENTIAL  4. SELECTION AND WITHDR AWAL OF SUBJECTS  
4.1. Inclusion Criteria 
Subjects  are eligible for participation in this s tudy if s/he meet s all of the following criteria : 
1. A diagnosis of non- infectious uveitis of any etiology  and from a mong those with anter ior-, 
intermediate -, posterior- or pan- uveitis  
2. Macular edema associated with non -infectious uveitis  defined by: 
• A retinal  thickness of  ≥ 300 microns in the central subfield, with fluid as measured 
by SD -OCT (using the Heidelberg SPECTRALIS® or Zeiss CirrusTM) and confirmed 
by the Central Reading Center  
3. ETDRS BCVA score of  ≥ 5 letters read (20/ 800 Snellen equivalent) and ≤ 70 letters read 
(20/40 Snellen equivalent) in the study eye 
4. Understands the language of the informed consent; willing and able to provide written 
informed consent prior to any study procedures; willing to comply with the instructions and attend all schedul ed study visits  
5. At least 18 years of age 
4.2. Exclusion Criteria  
4.2.1. Ophthalmic Exclusion Criteria  
Subjects are ineligible for participation  in this study  if s/he meet s any of the following criteria : 
1. Has significant media opacity in the study eye precluding evaluation of the retina and 
vitreous  
2. Has macular edema with etiology other than uveitis  
3. Any active ocular disease or infection in the study eye other than uveitis 
4. Intraocular pressure > 22 mmHg or uncontrolled glaucoma (open angle or angle clo sure)  
in the study eye at Visit 1 ; subjects are not excluded  if IOP is ≤ 22 mmHg in the study 
eye with no more than 2 IOP lowering medications  
5. History of any vitreoretinal surgery ( examples include but are not limited to scleral 
buckle, retrieval of a dro pped nucleus or intraocular lens) in the study eye ; prior 
photocoagulation and IVT injections are acceptable; prior cataract extraction , Yttrium-
Aluminum-Garnet laser capsulotomy, and pars plana vitrectomy is allowed, but must have been performed at least 3 months prior to Visit 2  
6. Has had  cyclodestructive procedures or filtration surgeries in the study eye in the 3 
months prior to Visit 2  
7. Has high myopia in the study eye defined as a spherical equivalent > -6 diopters or an 
axial length ≥ 26 mm  
8. Has had photocoagulation or cryotherapy in the study eye within the 6 months prior to Visit 2   
CLS1001- 301 Clinical Protocol  Clearside Biomedical, Inc.  
Version 4.0 12 April 2017  Page 17 of 65 
CONFIDENTIAL  9. Has had any intravitreal injection of anti- VEGF treatment (bevacizumab, aflibercept, 
pegaptanib or ranibizumab) in the st udy eye in the 30 days prior to Visit 2   
10. In the study eye, an y topical ocular corticosteroid in the 10 days prior to Visit 2 ; 
intraocular and periocular corticosteroid injection in the 2 months prior to Visit 2 ; an 
OZURDEX implant in the 6 months prior to Visit 2 ; RETISERT or ILUVIEN implant in  
the 3 years prior to Visit 2  
4.2.2. General Exclusion Criteria   
Subjects are not  eligible for participation in this study if s/he meet s any of the following criteria : 
11. Female subjects who are pregnant, lactating or planning a pregnancy. Females of 
childbearing potential must agree to submit to a pregnancy test at screening and agree to use an acceptable method of contraception throughout participation in the study.  
Acceptable methods of contraception include double barrier methods (condom with 
spermicide or diaphragm with spermicide), hormonal methods (oral contraceptives, implantable, transdermal, or injectable contraceptives), or an intrauterine contraceptive 
device with a documented failure rate of less than 1% per year.  Abstinence may be 
considered an acceptable method of contraception at the discretion of the Investigator, but the subject must agree to use one of the acceptable birth control methods if she becomes sexually active.  
12. Any uncontrolled systemic disease that , in the opinion of the Investigator, would preclude 
participation in the study (e.g., unstable medical status including uncontrolled elevated 
blood pressure, cardiovascular disease, and glycemic control) or put the subject at risk 
due to study treatment or procedures 
13. Likely need for hospitalization or surgery within the study period, including planned elective surgery or hospitalization that cannot be deferred 
14. Hypersensitivity to any component of the CLS -TA, fluorescein  or to topical anesthetics  
15. Is currently enrolled in an investigational drug or device study or has used an 
investigational drug or device within 30 days of Visit 2  
16. Has used acetazolamide (Diamox
®) 1 week  prior to Visit 2  
17. Has taken systemic corticosteroids  at doses greater than 20 mg per day for oral 
prednisone (or equivalent for other corticosteroids) in the 2 weeks prior to Visit 2; subjects on 20 mg or less per day can be enrolled if no increase in dos ing is anticipated 
for the duration of the study ; decreases and termination of dose are allowable during the 
study 
18. Is cu rrently using prescribed nonsteroidal anti-inflammatory drugs (excluding over-the-
counter use) unless the dose has been stable for at least 2 weeks  prior to Visit 2 , and no 
increase in dosing is anticipated for the study duration; decreases and termination of dose 
are allowable during the study 
19. Is currently using prescribed immunomodulatory therapies, unless the dose has been 
stable for at least 2 weeks  prior to Visit 2 , and no increase in dosing is anticipated for the 
study duration; decreases and termination of dose are allowable during the study 
CLS1001- 301 Clinical Protocol  Clearside Biomedical, Inc.  
Version 4.0 12 April 2017  Page 18 of 65 
CONFIDENTIAL  20. Has taken any fingolimod or any other drug in the 6 weeks prior to Visit 2 , where the 
drug is known to induce macular edema 
4.3. Subject Discontinuation/ Withdrawal from Clinical Study  
Subjects may withdraw from the study at any time and for any reason without obligation.  
Subjects may be removed from the study at the Investigator’s discretion.  Subjects who 
discontinue for any reason will not be replaced and their subject numbers will not be reassigned or re-used. 
If a subject withdraws from the study or if the Investigator removes a subject from the study, the 
Investigator should make every attempt to complete all Visit 8  assessments (Section 5.1.10.) .  If 
an SAE is unresolved at the time of the subject’s final study visit, investigator should make every 
attempt to follow up until the S AE is r esolved or stabilized, the subject is lost to follow-up, or 
there is some other resolution of the event.  If at any time during the study a subject is considered 
at immediate risk for a vision -threatening event due to study participation, the subject should be 
treated as soon as necessary, with the investigator determining  appropriate care or additional 
therapy  (Section  6.2.2.).  Subjects should not be discontinued from the study due to additional 
therapy or due to an AE unless the Investigator determines it to be in the subject’s best interest. 
4.3.1. Discontinuation of the Clinical Study  
The study or parts of the study may be discontinued by the Sponsor or at the recommendation of 
an Investigator after consultation with Sponsor, at any time.   This may be based on a significant 
number of AEs  of a similar nature that warrant such action or at the request of the Sponsor. 
If the clinical study is prematurely terminated or suspended, the Sponsor will inform the 
Investigators and the regulatory authorities of the termination/suspension and the reason(s) for the termination/suspension.  The Investigator should promptly notify th e IEC/IRB of the 
termination or suspension and of the reasons. 
  
4.3.2. Discontinuation of a Clinical Study Site  
The Sponsor reserves the right to close the investigational site, or terminate the study in its 
entirety at any time, for reasonable cause. Reasons for the closure of any investigational site or 
termination of a study may include:  
• Failure of the Investigator to accrue subjects into the study at an acceptable rate  
• Failur e of the Investigator to comply with applicable regulations and GCPs 
• Submission of knowingly false information from the research facility to the sponsor, FDA, or other regulatory authorities 
• Insufficient adherence to protocol requirements and procedures 
If the study is prematurely discontinued, all study data must be returned to the Sponsor.  
Additionally, the site must conduct final disposition of all unused study drugs in accordance with 
Sponsor procedures.  Study termination and follow-up will be performed in compliance with the 
conditions set forth in regulatory guidelines. 
CLS1001- 301 Clinical Protocol  Clearside Biomedical, Inc.  
Version 4.0 12 April 2017  Page 19 of 65 
CONFIDENTIAL  5. PROCEDURES  
5.1. Visit Description  
5.1.1. General Procedures  
The study will consist of up to 8 s tudy visits over a maximum of 27 weeks .  Subjects are 
expected to  attend all study visits.  All ocular assessments at Visit 1 and Visit 8 will be performed 
on both eyes. IOP will be collected in both eyes at all visits. All other o cular assessments at all 
other visits ( Visits 2 -7) will be performed on the study eye only.  S ubjects will be screen ed for 
entry (Visit 1) and then return to the clinic within 1 4 days to be randomized/treated  (Visit 2).  At 
randomization, subjects will receive either a single , unilateral,  suprachoroidal injection of 4 
mg/100 µL CLS- TA or a single, unilateral sham inject ion procedure in the study eye. Subjects 
will be assessed  post injection  for safety .  Additional safety follow-up visits will occur monthly 
for 24 weeks . Subjects will receive a second injection of either 4  mg/100 µL CLS- TA or a sham  
injection procedure at Visit 5  (Week 12 ) based on their original randomization at Visit 2 . The 
final study visit will occur at Visit 8 ( Week 2 4).  
5.1.2. Re-screening Procedures   
 
A subject who is first designated as a screen failure prior to being randomized may be rescreened up to 2 additional times , for a total of three screenings , upon Sponsor approval. Subjects who are 
re-screened are required to sign a new consent form.  
5.1.3. Visit 1 – Screening  (Day -14 to -1) 
At Visit 1, subjects will be screened for eligibility.  Before any study -specific assessments are 
performed, written informed consent will be obtained for each subject.  During Visit 1, the 
following procedures will be performed: 
1. Obtain written informed consent 
2. Assign subject number 
3. Collect demographics, medical  and ocular history    
4. Review current and prior concomitant medications  
5. Measure resting heart rate and blood pressure  
6. Collect blood and urine for central lab tests prior to FA, including serum  pregnancy test 
on females of childbearing potential 
7. Perform op hthalmic assessments on both eyes:  
a. ETDRS BCVA  
b. Slit-lamp biomicroscopy, including dilated lens grading   
c. IOP  
d. Dilated indirect ophthalmoscopy 
e. Fundus photography  
CLS1001- 301 Clinical Protocol  Clearside Biomedical, Inc.  
Version 4.0 12 April 2017  Page 20 of 65 
CONFIDENTIAL  f. SD-OCT  
g. FA   
8. Perform a review of systems  
9. Verify subject eligibility based on Inclusion/Exclusion requirements 
10. Determine study eye  based upon eye specific eligibility  criteria  
11. Schedule subject to return for Visit 2, Randomization/Treatment   
 
NOTE:   All images (SD -OCT, fundus photographs and FA) should be uploaded to the 
Central Reading Center. It will take approximately 2 business days for the Central 
Reading Center to confirm eligibility and the Central Laboratory report to arrive.  Allow 
sufficient time between Visit 1 and Visit 2 in order to confirm eligibility through the 
Central Reading Center and Central Laboratory reports.  
5.1.4. Visit 2 – Randomization/Treatment (Day 0) 
Visit 2 must occur within 14 days of Visit 1 (Screening) and may only occur once a subject 
qualifies for randomization, which includes central lab results being received and reviewed and 
confirmation of qualification by the Central Reading Center.   
Once eligibility is confirmed, subjects will be randomized via the IRT to receive a single, 
unilateral , suprachoroidal injection of CLS-TA (4 mg/100 µL) or a single, unilateral sham 
injection procedure.  Once randomized, subjects will receive an additional single, unilateral 
suprachoroidal injection of CLS-TA (4 mg/100 µL) o r a single, unilateral sham injection 
procedure approximately 12 weeks later (Visit 5).  Subjects will remain in the same treatment 
arm for the duration of participation in the study.  
The following procedures will be performed: 
5.1.4.1. Pre-Injection Procedures  
The following must be performed prior to the injection  (the same day as the injection) : 
1. Assess for AEs  
2. Review changes to concomitant medications  
3. Review central lab results for any clinically significant abnormalities  that would exclude 
the subject from ent ry 
4. Review the results received from the Central Reading Center to confirm that subject 
qualifies based on CST 
5. Review eligibility base d on Inclusion/Exclusion criteria 
6. Measure resting heart rate and blood pressure  
7. Perform ophthalmic assessments on the stud y eye only, unless otherwise designated:  
a. ETDRS BCVA  
b. Slit-lamp biomicroscopy, including dilated lens grading   
CLS1001- 301 Clinical Protocol  Clearside Biomedical, Inc.  
Version 4.0 12 April 2017  Page 21 of 65 
CONFIDENTIAL  c. IOP (both eyes)  
d. Dilated  ophthalmoscopy 
e. SD-OCT and upload images  to the Central Reading Center  
8. Administer VFQ -25 and EQ -5D 
9. Collect a blood sample from those subjects participating in the PK procedure ; blood must 
be collected PRIOR to dosing 
10. Log onto the IRT system and randomize subject   
5.1.4.2. Injection Procedure and Immediate Post- Injection  Assessments  
Injection should be performed the same day as the pre-injection procedures.  For details on the 
injection procedure, please see the Manual of Procedures. The injecting physician and supporting 
study staff who are present during the injection are unmasked on a per subject basis. Unmasked 
personnel should not perform assessments for that subject at Visits 3 ,4,6,7 and 8. Unmasked 
personnel may also perform pre - and post- injection  assessments, except BCVA, at Treatment 
visits (Visits 2 and 5)  if masked staff are not available. 
1. Confirm study eye 
2. Retrieve study  drug kit  number assigned by IRT 
3. Prepare eye for injection  per the investigator’s standard practice    
4. The UNMASKED injecting investigator should a dminister suprachoroidal injection of 
CLS-TA or perform the sham injection procedure to the study eye; s ee Ma nual of 
Procedures  for detailed instructions 
5. Immediately following the  injection,  assess study eye by indirect ophthalmoscopy 
5.1.4.3. Post-Injection Procedures  
The following assessments must occur following the injection : 
1. Assess for AEs  
2. Review changes to concomitant medications  
3. Perform ophthalmic assessments on the study eye only:  
a. Perform slit -lamp biomicroscopy  
b. Perform  indirect ophthalmoscopy 
c. Evaluate IOP 10 - 30 minutes post injection 
• If IOP remains elevated, subject must remain on site until IOP is u nder 
control per investigator judgment 
• If IOP is  < 30  mmHg , the subject may leave the clinic  
4. Schedul e subject to return for next visit 
 
CLS1001- 301 Clinical Protocol  Clearside Biomedical, Inc.  
Version 4.0 12 April 2017  Page 22 of 65 
CONFIDENTIAL  5.1.5. Visit 3  – Week 4  Post Randomization Follow- Up (Day 28 ±5) 
Visit 3  will occur approximately 4 weeks  post randomization . The visit should be 28 ±5 days 
from Visit 2. T he following Visit 3 procedures will be performed by masked study staff: 
1. Assess for AEs  
2. Review changes to concomitant medications   
3. Perform ophthalmic assessments on the study eye only, unless otherwise designat ed:  
a. ETDRS BCVA  
b. Slit-lamp biomicroscopy, including dilated lens grading   
c. IOP (both eyes)  
d. Dilated  indirect ophthalmoscopy 
e. SD-OCT and upload images  to the Central Reading Center  
4. Collect a blood sample from those subjects participating in the PK procedure 
5. Schedule s ubject to return for next visit 
5.1.6. Visit 4 – Week 8  Post Randomization Follow- up Visit ( Day 56 ±5) 
Visit 4  will occur approximately 8 weeks  post randomization . The visit should be 56 ± 5 days 
from Visit 2. The following Visit 4 procedures will be pe rformed by masked study staff:  
1. Assess for AEs  
2. Review changes to concomitant medications   
3. Perform ophthalmic assessments on study eye only, unless otherwise designated:  
a. ETDRS BCVA  
b. Slit-lamp biomicroscopy, including dilated lens grading   
c. IOP (both eyes)  
d. Dilated indirect ophthalmoscopy 
e. SD-OCT and upload images to the Central Reading Center  
4. Schedule subject to return for next visit 
5.1.7. Visit 5 – Week 12 – TREATMENT VISIT 2 (Day 84 ±5) 
Visit 5 will occur approximately 12 weeks post randomization.  At Visit 5, subjects will receive 
their second, single, unilateral study drug treatment.  The randomization arm  initially assigned to 
a subject will remain the same throughout the study. The treatment must be administered by an 
UNMASKE D injecting physician only.   
5.1.7.1. Pre-Injection Procedures  
The following must be performed prior to the injection  (the same day as the injection) : 
1. Assess for AEs  
CLS1001- 301 Clinical Protocol  Clearside Biomedical, Inc.  
Version 4.0 12 April 2017  Page 23 of 65 
CONFIDENTIAL  2. Review changes to concomitant medications  
3. Measure resting heart rate and blood pressure  
4. Confirm study eye  
5. Perform ophthalmic assessments on the study eye only, unless otherwise designated:  
a. ETDRS BCVA  
b. Slit-lamp biomicroscopy, including dilated lens grading   
c. IOP (both eyes)  
d. Dilated indirect ophthalmoscopy 
e. SD-OCT and upload images  to the Central Readi ng Center  
6. Collect a blood sample from those subjects participating in the PK procedure ; blood draw 
must be collected PRIOR to dosing 
5.1.7.2. Injection Procedure and Immediate Post -Injection Assessments  
For details on the injection procedure, please see the Manual of Procedures . The Visit 5 injection 
procedure should be identical to the Visit 2 injection procedure. 
1. Confirm study eye 
2. Retrieve study drug kit number assigned by I RT  
3. Prepare eye for injection per the investigator’s standard practice  
4. The UNMASKED injecting investigator should a dminister a suprachoroidal injection of 
CLS-TA or perform the sham injection procedure in the study eye; s ee Manual of 
Procedures  for detailed instructions 
5. Immediately following the  injection,  assess study eye by indirect ophthalmoscopy 
5.1.7.3. Post-Injection Procedures  
The following assessments must occur following the injectio n: 
1. Assess for AEs  
2. Review changes to concomitant medications  
3. Perform ophthalmic assessments on the study eye only :  
a. Perform slit -lamp biomicroscopy  
b. Perform  indirect ophthalmoscopy 
c. Evaluate IOP 10 - 30 minutes post injection 
• If IOP remains elevated, subject must remain on site until IOP is under 
control per investigator judgment 
• If IOP is < 30 mmHg, the subject may leave the clinic  
4. Schedule subject to return for next visit 
CLS1001- 301 Clinical Protocol  Clearside Biomedical, Inc.  
Version 4.0 12 April 2017  Page 24 of 65 
CONFIDENTIAL  5.1.8. Visit 6 – Week 16 Post Randomization Follow -up Visit (Day 112 ±5) 
Visit 6 will occur approximately  16 weeks post randomization. The visit should be 112 ± 5 
days from Visit 2. The following Visit 6 procedures will be performed by masked study staff:  
1. Assess for AEs  
2. Review changes to concomitant medications   
3. Perform ophthalmic assessments on study eye only, unless otherwise designated:  
a. ETDRS BCVA  
b. Slit-lamp biomicroscopy, including dilated lens grading   
c. IOP (both eyes)  
d. Dilated indirect ophthalmoscopy 
e. SD-OCT and upload images  to the Central Reading Center  
4. Schedule subject to return for next visit 
5.1.9. Visit 7 – Week 20  Post Randomization Follow -up Visit (Day 140 ±5) 
Visit 7 will occur approximately 20 weeks post randomization. The visit should be 140 ± 5 
days from Visit 2. The following Visit 7 procedures will be performed by masked study staff: 
1. Assess for AEs  
2. Review changes to concomitant medications   
3. Perform ophthalmic assessments on study eye only, unless otherwise designated: 
a. ETDRS BCVA  
b. Slit-lamp biomicroscopy, including dilated lens grading   
c. IOP (both eyes)  
d. Dilated indirect ophthalmoscopy 
e. SD-OCT and upload images  to the Central Reading Center  
4. Schedule subject to return for next visit 
5.1.10. Visit 8 – Week 24  End of Study Visit (Day 1 68 ±5 ) or Early Termination Visit  
Visit 8 will occur approximately 24 weeks post randomization. The visit should be 168 ± 5 days 
from Visit 2  or at the time of early termination. The following Visit 8 procedures will be 
performed by masked study staff:  
1. Assess for AEs  
2. Review changes to concomitant medications   
3. Measure resting heart rate and blood pressure  
4. Collect blood and urine for central lab tests prior to FA  (including serum  pregnancy test 
on females of childbearing potential) 
CLS1001- 301 Clinical Protocol  Clearside Biomedical, Inc.  
Version 4.0 12 April 2017  Page 25 of 65 
CONFIDENTIAL  5. Collect a blood sample from th ose subjects participating in the PK procedure  
6. Perform a review of systems  
7. Administer VFQ -25 & EQ -5D 
8. Perform ophthalmic assessments on both eyes:  
a. ETDRS BCVA  
b. Slit-lamp biomicroscopy, including dilated lens grading   
c. IOP  
d. Dilated indirect ophthalmoscopy 
e. Fundus photography and upload images to the Central Reading Center    
f. SD-OCT and upload images  to the Central Reading Center   
g. FA and upload images to the Central Reading Center   
5.1.11. Unscheduled Visit  
To ensure subject safety during the trial, any subject who  requires additional follow-up during 
the study for any reason should see the Investigator, even if such a visit does not fall within a 
scheduled study visit. The masked investigator/staff should complete assessments for an unscheduled visit whenever possible. 
Any visit that occurs between the regularly scheduled visits must be documented in the 
Unscheduled Visit pages of the Electronic Case Report Form (eCRF). If the patient is 
discontinuing at the Unscheduled Visit, the procedures for Visit 8 (Week 24) should be 
completed as described in Section 4.3 and captured on the Visit 8 eCRFs , not on the eCRFs for 
an Unscheduled Visit. 
CLS1001- 301 Clinical Protocol  Clearside Biomedical, Inc.  
Version 4.0 12 April 2017  Page 26 of 65 
CONFIDENTIAL  6. TREATMENT OF SUBJECTS 
6.1. Treatments to be Administered  
Treatment will consist of two  unilateral suprachoroidal injections of 4 mg of CLS -TA in 100 µL, 
or two sham injection  procedures, administered 12 weeks  apart, according to  the randomization 
assignment .  
Subjects will be randomized to either of the following groups:  
1. Active: 4 mg CLS-TA, triamcinolone acetonide injectable suspension, 40 mg/mL in         
100 µL 
2. Control: sham injection procedure 
Approximately 150 subjects will be randomized in a 3:2 ratio where approximately 90 subjects 
will be randomized to the Active arm  and approximately 60 subjects will be randomized to the 
Control arm. The CLS -TA injection s, or sham injection procedu res, occur at Visit 2 (Day 0) and 
at Visit 5 (Day 84 ± 5).   
The study drug kits will be supplied to the site.  Each subject  will be randomized to a study arm 
and be assigned a study drug kit at both Visit 2 (Day 0) and again at Visit 5 (Week 12).  Each kit 
will be identical (either two active kits or two sham kits). Each kit will contain the following 
components: 
Active Kit:  
• Vial of CLS -TA (40 mg/mL) 
• Clearside microinjector  
• Vial access device (for drug transfer)  
• 900 µm needle 
• 1100 µm needle 
Sham  Kit:  
• Vial of CLS -TA (40 mg/mL) 
• Clearside microinjector  
• Vial access device (for drug transfer)  
• Sham hub 
All study drug injection s may only be performed by trained I nvestigators.  Training will be 
documented by the Sponsor in writing.  Training documentation will be maintained at the site as 
well as with the Sponsor.     Detailed instructions on the s tudy drug injection procedure can be found in the Manual of 
Procedures . 
CLS1001- 301 Clinical Protocol  Clearside Biomedical, Inc.  
Version 4.0 12 April 2017  Page 27 of 65 
CONFIDENTIAL  6.1.1. Study Eye Determination  
The study eye will be the eye receiving the CLS -TA injection or the sham injection procedure 
depending upon the group to which the subject is randomized. The determination of the study 
eye will be based on Visit 1 (screening) information only. 
If both eyes meet study criteria, then the eye , in the Investigator’s opinion, with the better chance 
of achieving an improvement in BCVA should be used as the study eye. If both eyes qualify for 
the study, and appear similar in their chance of improvement, the right eye should be designated as the study eye. The eye that is not designated as the study eye will be denoted as the fellow 
eye. 
6.1.2. Treatment  of the Fellow Eye (Non- Study Eye)  
Subjects may have bilateral disease, but only one study eye may be enrol led.  
Ocular therapy for the fellow eye is not subject to the requirements of this protocol. Systemic 
therapy for diseases of the fellow eye is subject to the list of prohibited medications below. L ocal 
medications are permitted for the fellow eye during the course of this trial. Medications used in 
the fellow eye will be recorded in the subject’s medical chart and the case report form (CRF).   
6.2. Concomitant Medications  
6.2.1. Prohibited Medications  
The list of prohibited medications provided below is not intended to be comprehensive, but 
rather to help guide the Investigator’s medical ju dgment. In cases where a subject  presents with a 
medication not included on the following list, or should there be any question on the part of the 
Investigator, Investigators are encouraged to confer with the Medical Monitor for any 
clarification.  
Use of the following medications are prohibited at any time during the study: 
• Increases  to topical ophthalmic NSAIDs in the study eye  
• Any corticosteroid implant (ie , Ozurdex®, Iluvien® or Retisert®) in the study eye 
• Topical, periocular or intravitreal corticosteroids in the study eye  
• Increases in dose of  systemic prednisone or other equivalent steroid (eg, dexamethasone), 
including, but not limited to, the following routes: oral, intravenous, intramuscular, in sufficient doses and/or for sufficient time such that the Investigator has concerns about additional ocular exposure to steroids in terms of safety and/or efficacy  
• Anti-angiogenic drugs (anti- VEGF) in t he study eye or systemically ( including 
pegaptanib sodium, bevacizumab, ranibizumab, aflibercept ) 
• Increases  to dose of systemic immunosuppressant drugs 
• Fingolimod or any other drug known to induce ME 
• Acetazolamide (Diamox
®) 
• Any i nvestigational drug or device 
CLS1001- 301 Clinical Protocol  Clearside Biomedical, Inc.  
Version 4.0 12 April 2017  Page 28 of 65 
CONFIDENTIAL  In cases where there is anticipated need for the above listed medications during the study or if a 
subject  presents to the Investigator having initiated treatment during the study with one of these 
medications or classes of medications, it is the responsibility of the Investigator to notify the 
Sponsor immediately. If additional therapy is necessary  to treat uveitis in the study eye  and 
normal standard of care requires these medications, they will be recorded in the subject’s case report form  and should follow the guidelines presented for rescue criteria . Subjects will not be 
discontinued from the study due to initiation/change in a prohibited medication. 
6.2.2. Additional Treatment  
If at any time during the study a subject is considered at immediate risk for a vis ion-threatening 
event, the Investigator should immediately follow best medical practice in the Investigator’s 
judgment for treating the subject. All additional therapy will be recorded in the subject’s  medical 
chart and the CRF.  
Rescue Criteria  
Beginning at Week 4 ( Visit 3), i f any of the following criteria are met in the study eye, 
the use of a treatment should be introduced. The therapy implemented is left to the 
discretion of the Investigator.   
• A decrease of  10 or more ETDRS BCVA letters read from baseline (Day 0)  
• An increase in CST of  ≥100 microns or 20%, whichever is lower, from baseline 
(Day 0)  based on the CST measurement at the clinical site 
• A ≥ 1.5-step increase from baseline (Day 0) in the level of inflammation (eg, 
anterior chamber cells or vitreous haze) or an increase from 3+ to 4+  
• In the investigator’s medical judgement , the uveitic complications in the study 
eye have not improved and the condition needs to be addressed  
6.3. Treatment  Compliance  
Study drug will only be administered by trained study investigators ( principal investigator or 
sub-investigator) in the office  at Visit 2  and at Visit 5. The injecting physician will be unmasked 
per patient.   No study drug will be dispensed to subjects ; therefore , subject treatment compliance 
is not applicable.   
The date and time of the injection will be recorded in the subject’s medical chart and the CRF.  All needles used and the needle length used for injection will also be recorded . All stu dy drug 
kits (and all the components of each of the kits , such as the vial, the microinjector , etc. ) will 
remain under the control of the study site staff at all times. Following injection, used 
microinjectors should be disposed of properly but used vials of study drug should be capped and 
maintained in the original box until accountability has been completed by the unmasked monitor. 
6.4. Drug Accountability 
Accountability of study drug kits will be conducted by an unmasked member of the site and verified by an unmasked monitor.  Accountability will be ascertained by performing 
reconciliation between the number of study drug cartons (kits and their components) sent to the 
CLS1001- 301 Clinical Protocol  Clearside Biomedical, Inc.  
Version 4.0 12 April 2017  Page 29 of 65 
CONFIDENTIAL  site, and the number used and unused at the time of reconciliation. Unmasked site staff will be 
queried about any discrepancies. 
Study drug shipment records will be verified and accountability performed by comparing the 
shipment inventory sheet to the actual quantity of drug and microinjector s received at the site.  In 
addition, receipt of study drug cartons will be confirmed via the I RT.  Accurate records of receipt 
and disposition of the study drug and microinjectors (eg , dates, quantity, subject number, kits 
used, kits unused, etc.) must be maintained by the unmasked investigator or his/her des ignee. 
Study drug will be stored ambient at 20 – 25o C (68 – 77o F) and this area should have limited , 
controlled access  with temperature monitoring .  
At the end of the study and after an unmasked monitor has verified study drug kit accountability, 
all stu dy drug (used and unused vials) and unused microinjector  components are to be returned to 
the Sponsor (or designee) or destroyed at the site an d documented per the site’s standard process. 
Any used microinjectors and vials of study drug involved in a product complaint must be 
maintained and returned to an unmasked person at the Sponsor (or designee).   All study drug and 
microinjector  accounting procedures must be completed before the study is considered complete. 
6.5. Masking / Unmasking  
Subject randomization assignment  will be protected using a masked allocation schedule created 
by a clinical allocation schedule system. Emergency unmasking of subjects by authorized 
clinical site perso nnel will occur via I RT according to procedures outlined in the Manual of 
Operations provided to the sites by the Sponsor. The Investigator should not unmask the 
subject’s randomization assignment without the Sponsor’s approval unless immediately required 
in response to a serious adverse event .  If the Sponsor was not notified prior to the unmasking 
event, the Investigator must immediately contact the Sponsor informing them as to the specific 
details of the occurrence. The Sponsor personnel involved in the collection, interpretation, 
analysis, review, or any decisions stemming from the study data will remain masked as to subject 
status for the duration of the study unless otherwise warranted. 
To maintain masking and minimize bias by the  Investigator,  sub- Investigator, all designated 
readers and graders, the subject , the Sponsor and monitors involved in reporting, obtaining 
and/or reviewing the clinical evaluations  for a particular subject  will not be aware of the specific 
randomization assignment for that subject. Only study staff who are designated by the 
Investigator to prepare and administer  study drug and conduct test article accountability may 
know the randomization assignment. Both the masked or unmasked Investigator and staff may 
participate in evaluations conducted during the screening visit. The unmasked Investigator may 
participate in pre- and post- injection ophthalmic exams, except BCVA, at treatment visits (Visit 
2 and 5). Otherwise unmasked personnel will not be involved in a subject ’s evaluations or 
assessments. Designee(s) will not discu ss the test article with other site personnel or the Sponsor 
monitors and will instruct patients to not discuss the study drug or appearance of the packaging 
with the Investigator, sub-Investigator(s) or any other study staff while the study is ongoing. This level of masking will be maintained throughout the conduct of the study. 
The external packaging for the test article and sham control will be identical.  
The PK vendor analyzing samples will be unmasked to subject randomization codes and 
demographics in order to evaluate exposure levels. During the conduct of the study, Sponsor 
CLS1001- 301 Clinical Protocol  Clearside Biomedical, Inc.  
Version 4.0 12 April 2017  Page 30 of 65 
CONFIDENTIAL  staff working directly on the study will not have access to  individually identifiable PK analysis 
data. 
If masking is compromised, any masked personnel who become unmasked will not conduct any 
further masked clinical evaluations with the subject  whose treatment has been unmasked. The 
investigational site will notify the IRB and Sponsor/designee; follow- up training will be 
required. 
CLS1001- 301 Clinical Protocol  Clearside Biomedical, Inc.  
Version 4.0 12 April 2017  Page 31 of 65 
CONFIDENTIAL  7. ASSESSMENTS OF EFFICACY  
 
7.1. Best Corrected Visual Acu ity (BCVA)   
Best Corrected Visual Acu ity (BCVA)  will be measured using ETDRS electronic visual acuity  
(eVA) . BCVA will be recorded as total letter score in each eye following refraction.  Visual 
acuity testing should precede any examination requiring contact with the eye.  
In order to provide standardization and well-controlled assessments of BCVA during the study, 
all BCVA assessments must be performed by trained staff who are certified on  the study 
procedure using certified VA equipment/ lanes . 
If eVA cannot be performed for any reason, BCVA will be measured using a standard ETDRS 
wall chart. If Roman letters are not familiar to the subject, Tumbling E charts may be used.  
7.2. Central Subfield Thickness as Measured by SD -OCT  
Retinal thickness and disease characterization will be assessed via spectral domain optical 
coherence tomography ( SD-OCT ) (Heidelberg SPECTRALIS® or Zeiss CirrusTM).  The SD -OCT 
instrument and technician must be certified p rior to screening any subjects. The technician is 
encouraged to use the same certified photography equipment throughout the subject’s study 
participation.   All photos should be taken by the same photographer, whenever possible, on each  
subject per research site.  Images will be sent to a central reading facility for analysis and 
interpretation in a masked fashion. 
7.3. Visual Function Questionnaire (VFQ -25)  
The VFQ -25 [25] consists of a base set of twenty-five vision- targeted questions  representing 
eleven visio n-related constructs, plus an additional single- item general  health rating question. 
The VFQ -25 takes approximately 10 minutes on average to administer in the interviewer format. 
A trained technician will administer  this questionnaire to the subject.  
7.4. EQ-5D  
EQ-5D is a standardized measure of health status developed to provide a simple, generic 
measure of health for clinical and economic appraisal.  EQ-5D is designed for self-completion by 
respondents. It is cognitively undemanding, taking only a few minutes to complete. Instructions 
to respondents are included in the questionnaire. Subjects unable to read may have the EQ- 5D 
read to them.  
7.5. Pharmacokinetics Assessments  
Approximately 25% of subjects  will be enrolled in the pharmacokinetic portion of the study from 
select sites . Blood samples for measurement of CLS -TA plasma concentrations will be collected 
from those subjects who consent at participating sites, by venipuncture by qualified study 
personnel. A single blood sample will be obtained from each subj ect at the following time points: 
Day 0 (pre-dose), Week 4 visit (any time during visit), Week 12 visit (pre-dose) and Week 24 
visit (any time during visit).  Blood samples will be processed and shipped to a central lab as 
outlined in the manual of procedur es for the study.  
CLS1001- 301 Clinical Protocol  Clearside Biomedical, Inc.  
Version 4.0 12 April 2017  Page 32 of 65 
CONFIDENTIAL  8. ASSESSMENTS OF SAFET Y 
8.1. Intraocular Pressure  
Intraocular pressure (IOP) will be measured by applanation tonometery and results will be 
recorded in mmHg. Where available, Goldmann applanation tonometry should be used at all 
visits. Tonopens may be used for post- injection pressure checks and in cases where no 
Goldmann is available. A single measurement will be made at approximately the same time of 
day. The technician is encouraged to use the same tonometry method for all pre -injection and 
non-injection measurements throughout the subject’s study participation. Tonometers must be 
calibrated for accuracy before the first subject screening at that site and according to the manu facturer specifications during the study, until the last subject has exited the study at that 
site. 
 
8.2. Slit-Lamp Biomicroscopy  
Slit-lamp biomicroscopy, including magnification, will be performed consistent with standard clinical practice. This procedure sho uld be conducted in the same manner for all subjects and 
will include an assessment of each of the following as normal or abnormal: eyelids, cornea, anterior chamber, iris and  lens. All abnormal findings will be described .  
 8.2.1 Cataract Lens Grading 
If an abnormal finding of cataract is noted for the lens  during the slit- lamp exam, the cataract 
should be assessed for nuclear opalescence, cortical opacity  and posterior subcapsular opacity. 
Graders must verify  train ing on the grading procedure provided in the Manual of Procedures. 
 
8.2.2 Anterior Chamber Cells  
Anterior chamber cells will be assessed clinical ly using a field size of 1 mm slit beam and using 
a standardized grading scale ranging from 0 to 4 +, as defined in Table 1 (SUN 2005).  
 
CLS1001- 301 Clinical Protocol  Clearside Biomedical, Inc.  
Version 4.0 12 April 2017  Page 33 of 65 
CONFIDENTIAL  Table 1: Anterior Chamber Cell Grading Scale 
Score  Cells in Field  
0 <1 
0.5+ 1-5 
1+ 6-15 
2+ 16-25 
3+ 26-50 
4+ >50 
 
8.2.3 Anterior Chamber Flare 
Anterior chamber flare will be assessed clinically via slit lamp  using a standardized scale ranging 
from 0 to 4, as defined in Table 2 (SUN 2005).  
Table 2: Anterior Chamber Flare Grading Scale 
Score  Description  
0 None 
1+ Faint  
2+ Moderate (iris and lens details clear)  
3+ Marked (iris and lens details hazy)  
4+ Intense (fibrin or plastic aqueous) 
 
8.3. Dilated Ophthalmoscopy  
A dilated fundus examination will include an assessment of each of the following as normal or 
abnormal: vitreous, retina, macula, choroid and optic nerve . All abnormal findings will be 
described .  
 8.3.1 Vitreous Haze  
Vitreous haze will be assessed clinically v ia indirect ophthalmoscopy using a standardized 
photographic scale ranging from 0 to 4, as defined in Table 3 (Nussenblatt 1985 as modified in 
Lowder 2011).  
CLS1001- 301 Clinical Protocol  Clearside Biomedical, Inc.  
Version 4.0 12 April 2017  Page 34 of 65 
CONFIDENTIAL  Table 3: Scale for Determining Degree of Vitreous Haze 
Score  Description  
0 no inflammation  
+0.5 trace inflammation (slight blurring of the optic disc margins and/or loss 
of the nerve fiber layer reflex)  
+1 mild blurring of the retinal vessels and optic nerve 
+1.5 optic nerve head and posterior retina view obscuration greater than +1 but 
less than +2  
+2 moderate blurring of the optic nerve head 
+3 marked blurring of the optic nerve head 
+4 optic nerve head not visible 
 
8.4. Fluorescein  Angiography 
Fluorescein angiography  (FA) images will be performed to examine the circulation of the retina. 
Study personnel who perform FA will be trained and certified by the central reading center prior 
to screening any subjects . Images will be sent to a central reading facility.   
8.5. Fundus Photograph y 
Fundus photographs will be collected to assess the disease and anatomical characteristics of the 
retina. Study personnel who perform FA will be trained and certified by the central reading 
center prior to screening any subjects. Images will be sent to a central reading facility.  
8.6. Review of Systems  
A review of body systems will include an assessment of each of the following as normal or 
abnormal: skin, cardiovascular, respiratory, neurological and musculoskeletal systems . All 
abnormal findings will be described . This exam  may be performed by any medical doctor or 
legally qualified personnel per local laws/regulations.  
8.7. Clinical laboratory tests  
Non-fasting blood and urine samples will be collected during the study. Samples will be sent to a 
central lab for analysis. Analytes to be evaluated are listed in  Table 4. 
CLS1001- 301 Clinical Protocol  Clearside Biomedical, Inc.  
Version 4.0 12 April 2017  Page 35 of 65 
CONFIDENTIAL  Table 4: Clinical Laboratory Analytes to be Tested 
 
 
8.8. Vital signs  
Resting heart rate and r esting blood pressure (systolic and diastolic, preferably on the same arm 
each time)  will be measured at Visits 1, 2, 5 and 8.  
 
8.9. Evaluation of Adverse Event s   
Adverse events will be monitored continuously during the study beginning at the time of the 
subject’s signing of the informed consent . Subjects will be instructed to report all AEs during the 
study. Subjects will be assessed for the occurrence of AEs at each visit. Thus, AEs may be 
reported by the subject, discovered by the study staff questioning or detected through study assessments. All AEs (serious and non-serious) must be recorded on the source documents and AE CRFs, regardless of the assumed causal relationship with the test article. The following information about each AE will be collected: severity, onset and resolution dates, frequency, seriousness, relationship to study treatment , action taken and outcome. Chemistry (serum)  Alanine amino transferase; serum albumin;  alkaline 
phosphatase; aspartate amino transferase; bilirubin, direct  
and total; total serum calcium; total carbon dioxide; serum chloride; total creatine kinase; serum creatinine; gamma glutamyl transaminase; glucose; lactate dehydrogenase; 
serum potassium; total serum protein; serum sodium; total 
cholesterol; triglycerides; urea  
Hematology  CBC including: hemoglobin (Hgb), platelet count (PLT), 
red blood cell (RBC), white blood cell (WBC) and 
hematocrit (Hct); WBC differentials of: basophils; eosinophils, lymphocytes, monocytes and total neutrophils 
Urinalysis (Macro)  Bilirubin; blood; glucose; ketone; protein; specific gravity;  pH 
Pregnancy (serum)a  
aWomen of childbearing potential at 
screening and study exit only β-human chorionic gonadotropin (βHCG) 
CLS1001- 301 Clinical Protocol  Clearside Biomedical, Inc.  
Version 4.0 12 April 2017  Page 36 of 65 
CONFIDENTIAL  8.9.1. Definition s 
An adverse event ( AE) is any untoward medical occurrence associated with the use of a drug in 
humans and does not have to have a causal relationship with study treatment.   
An AE can therefore be any unfavorable and unintended sign (that could include a clinically 
significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.  
Whenever possible, the Investigator should group signs or symptoms that constitute a single diagnosis under a single AE term (eg, “cough, rhinitis and sneezing” might be grouped together as “upper respiratory tract infection”).  
An AE  may  include: 
• Any sign, medical diagnosis or symptom 
• Any new undesirable medical occurrence or unfavorable or unintended change of a pre-
existing condition that occurs during or after test article administration .  
NOTE :  
o The disease under study (ie, non- infectious uveitis) or sign or symptom associated 
with the disease are not considered adverse events unless more severe than 
expected for the subject’s condition 
o Symptoms associated with disease,  which are consistent with the subject's usual 
clinical course are not considered adverse events,  unless the subject experiences 
worsening of symptoms more severe than expected or unless the symptom(s) meet the criteria for an SAE  
• Clinically significant (a s determined by the Investigator)  laboratory abnormalities, 
ophthalmic assessments or vital signs (eg, requiring discontinuation of test article, specific treatment or a change in subject management). If possible, abnormal laboratory results or changes in vital signs that meet the definition of an AE should be reported as a clinical diagnosis rather than the abnormal laboratory value (eg, “hypertension” rather than “blood pressure increased”) 
All baseline conditions and AEs identified during the clinical study from the time the subject signs the informed consent, through the subject’s last day of study participation, will be documented on the appropriate CRF. Special considerations include:  
• Baseline conditions are not considered adverse events unless the condition worsens following study drug administration   
• Elective procedures or routinely scheduled treatments are not considered AEs; however, an untoward medical event occurring during the pre-scheduled elective procedure should be recorded as an AE  
• Changes in pre-existing medical conditions, including changes in severity, frequency or character, during the protocol-defined reporting period should be recorded as AEs 
CLS1001- 301 Clinical Protocol Clearside Biomedical, Inc.  
Version 4.0 12 April 2017  Page 37 of 65 
CONFIDENTIAL  •Overdose of either study drug or concurrent medication without any signs or symptoms is
not considered adverse events
•Death itself is not considered an AE; it is instead the outcome of an AE
•Pregnancy is not considered an AE. Reports of pregnancy will be reported to the Sponsorin accordance with Section 8.9.4
A treatment -emerg ent AE (TEAE)  is any AE temporally associated with the use of the study 
drug, whether or not considered causally related to the study drug  that occurs after the subject 
receives the first dose of study drug.  
A serious adverse event  (SAE ) includes any event , if in the view of either the Investigator or 
the Sponsor, results in any of the following outcomes. 
•Death
•Life-threatening (ie, if in the view of the Investigator or Sponsor, the event’s occurrence
places the subject at immediate risk of death) ; it does not include an AE that, had it
occurred in a more severe form, might have caused death
•In-patient hospitalization or prolongat ion of existing hospitalization
o“In-patient” hospitalization means the subject has been formally admitted to a
hospital for medical reasons.  This may or may not be overnight.  It does notinclude presentation at a casualty or emergency room.
•A persistent or significant incapacity or substantial disruption of the ability to conductnormal life functions
•A congenital anomaly in the offspring  of a subject who received study drug
•Important medical events that may not result in death, be life -threatening or require
hospitalization may be considered an SAE when, based upon appropriate medicaljudgment, they may jeopardize the subject and may require medical or surgicalintervention to prevent one of the out comes listed in this definition
oExamples of such medical events include allergic bronchospasm requiringintensive treatment in an emergency room or at home, blood dyscrasias orconvulsions that do not result in inpatient hospitalization, or the development of
drug dependency or drug abuse.
The intensity of ea ch A E will be graded using National Cance r Institute (NCI) Common 
Terminology Criteria for Adverse Events (CTCAE) v 4.03. The  criteria can be accessed at: 
http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf . 
The term “s evere” is a measure of i ntensity. A s evere AE i s not  necessarily a serious  AE. 
Gr
ade refer
s to the severity of the AE. The CTCAE displays Grades 1 through 5 with unique 
clinical descriptions of severity for each AE based on this general guideline: 
CLS1001- 301 Clinical Protocol Clearside Biomedical, Inc.  
Version 4.0 12 April 2017  Page 38 of 65 
CONFIDENTIAL  Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic 
observations only; intervention not indicated 
Grade 2  Moderate; minimal, local or noninvasive intervention 
indicated; limiting age -appropriate instrumental activities of 
daily living (ADL)  
Grade 3  Severe or medically significant but  not immediately life -
threatening; hospitalization or prolongation of the hospitalization indicated; disabling; limiting self -care ADL  
Grade 4  Life threatening consequences; urgent intervention indicated 
Grade 5  Death related to AE  
Causality is the relationship of an AE to study drug and will be assessed by the investigator as 
follows in Table 5:  
Table 5: Causality Definitions  
Causality  Definition  
Related  There is a reasonable causal association with 
administration of the study drug; the event is confirmed 
by stopping and/or restarting the drug or is not explained 
by any other reasonable hypothesis  
Not related  There is no causal or temporal relationship to the study 
drug; related to other etiologies s uch as concomitant 
medications or conditions  
8.9.2. Adverse Event R
eporting Procedures  
The Investigator will assess subjects for the occurrence of AEs at all scheduled and unscheduled 
visits. The occurrence of AEs should be sought by non- direct questioning of the subject at each 
visit. At each study visit, study personnel should ask the following question: “ Have you had any 
problems since your last visit?" Adverse events may also be detected when they are volunteered by the subject during and between visits or through study assessments. All AEs (serious or non-
serious) reported by the subject will be reviewed by a qualified physician participating as an 
investigator in the study and must be recorded on the source documentation and AE CRF provided. 
8.9.3. Prompt Reporting of SAEs to the Sponsor  
An adverse event that is serious must be reported on an SAE form to the Sponsor immediately, 
but no later than 24 hours after the investigator becomes aware of the event.  
CLS1001- 301 Clinical Protocol Clearside Biomedical, Inc.  
Version 4.0 12 April 2017  Page 39 of 65 
CONFIDENTIAL  Prompt reporting of a SAE requires: 
•Completion and transmission of SAE information  to the Sponsor within 24 hours of the
investigator ’s knowl edge  of the event.  The SAE information should be completed as
thoroughly as possible before transmittal to the Sponsor.  It is very important that the
investigator provide his/her assessment of causality to study treatment  at the time of
initial reporting  of the SAE.
•Prompt reporting of additional information for previously reported SAEs should follow
the same reporting timeframe as initial reports .
If an ongoing SAE changes in intensity or the relationship to study drug, a follow-up SAE report should be sent to the Sponsor within 24 hours after the clinical site becomes aware of the change in status.  
8.9.4. Pregnancy Reporting  
Pregnancy alone is not an AE. However, any report of pregnanc y during a female subject’s 
participation in the study must be promptly reported to the Sponsor as soon as the Inve stigator is 
notified, using a Pregnancy Report Form . 
The Sponsor should be notified of any updates on the status of the pregnancy as soon as the information becomes available and the site will complete the Pregnancy F ollow -up Form . 
8.9.5. Transmission of SAE Reports and Pregnancy Forms 
SAE reporting information and pregnancy reporting information should be transmitted to the 
Sponsor via email or  fax as provided below.  
Chiltern, Inc. 
GlobalSAEInbox@chiltern.com  
Toll free fax US:   888-726-8416
Toll free fax  India : 91-2266-459-811
Please refer to the study reference binder for complete contact information.  Contact the Medical 
Monitor with any questions regarding a potential SAE.  
8.9.6. Regulatory Reporting Requirements for SAEs  
The Sponsor will determine which SAEs qualify for expedited reporting. Reports of those SAEs that qualify for expedited reporting will be unmasked for the individual subject and submitted to regulatory agencies in accordance with applicable local regulation. Expedited reports will also be distributed to Investigators without revealing the treatment assignment and will be submitted to IRB/IEC in accordance with institu tional guidelines and local regulation. 
CLS1001- 301 Clinical Protocol Clearside Biomedical, Inc.  
Version 4.0 12 April 2017  Page 40 of 65 
CONFIDENTIAL  8.9.7. Follow- up of AEs and SAEs  
All AEs and SAEs reported during study conduct must be followed until resolution, until the 
condition stabilizes, until the event is otherwise explained, or the subject is lost to follow-up.  Subjects will be followed for any treatment- related SAEs reported at the end of participation 
until the condition stabilizes, t he event is otherwise explained , the subject is lost to follow -up or 
the subject withdraws consent.   
NOTE:  “Resolution” means the subject has returned to baseline state of health or the 
Investigator does not expect any further improvement in the subject’s condition or does not expect worsening of the AE.  
For a non- serious AE that is first identified on the last scheduled contact,  the event must be 
recorded on the AE CRF with the current status noted, but no further follow-up needs to be performed.  
Post-Study SAEs:  Investigators are not obligated to actively seek SAE information in former 
study participants, however, any new SAE r eported by the subject to the Investigator that occurs 
after the last scheduled contact and is determined by the Investigator to be associated with the use of study drug, should be reported to the Sponsor. The Investigator should follow related SAEs ide ntified after the last scheduled contact until the event has resolved or stabilized or the 
subject is lost to follow -up.  
CLS1001- 301 Clinical Protocol  Clearside Biomedical, Inc.  
Version 4.0 12 April 2017  Page 41 of 65 
CONFIDENTIAL  9. STATISTIC AL CONSIDERATIONS  
A detailed statistical analysis plan will be prepared for this study.  The plan will contain a 
discussion of the statistical methods, a description of the computational algorithms and data 
handling conventions, and specifications for the data summaries and listings.  It will be finalized before database lock.  
9.1. Randomization  
There will be approximately 150 subjects randomized at a 3:2 ratio to the two treatment arms. 
Assignment of subjects to treatment arms will be performed via IRT. 
9.2. Determination of Sample Size  and Level of Significance  
The sample size of approximately 150 subjects at approximately 50 center s was based on clinical 
considerations appropriate for a randomized  Phase 3 study.  
With a total sample size of 150 subjects in a 3:2 randomization this study will have 90% power to detect a difference between treatments if the actual proportion of subject s  showing 
improvement of 15 letters  or more is 0.60 for the treated group and 0.34 in the sham group. 
Power analyses were conducted based on an assumption of the proportion of subjects gaining 15 or more letters in the CLS -TA treated arm to be 0.6 while those in the untreated (sham) arm 
gaining 15 or more letters to be 0.13. Calculations for power based on lower confidence limit 
used the observed result for the treated group and subtracted the lower confidence interval for the 
difference (0.2636) from that diffe rence to estimate the sham result (0.3364).  
Power analysis assumes that the parameter estimates are based on population values not sample 
results.   An observed sample result is expected to overestimate population differences 50% of the 
time.   By using a lower confidence interval estimate can be used to mitigate the risk that the 
sample estimate was larger than the population value.  In this case, a lower 90% one sided confidence interval the difference in proportions was used to calculate an offset from the 
observed result that would be the lowest likely population estimate. The offset was added to the estimate for the control group to create conservative estimates.  The conservative power 
calculations were performed based on the conservative estimates.  
9.3. Subje ct Disposition, Demographic and Baseline Characteristics  
Subject disposition, demographic, and baseline characteristics will be summarized descriptively 
by treatment group and overall. 
9.4. Analysis  Populations  
 
9.4.1 Safety Population 
Safety population will include all randomized subjects who are administered at least one dose of the study drug. All safety analyses will be based on safety population. 
9.4.2 Intent -to-Treat Population  
CLS1001- 301 Clinical Protocol Clearside Biomedical, Inc.  
Version 4.0 12 April 2017  Page 42 of 65 
CONFIDENTIAL  Intent- to-treat (ITT) population includes all randomized subjects who have received at least one 
study treatment. Subjects will be analyzed as originally allocated after randomization. ITT 
population will be used for efficacy analyses.   
9.4.3 Per Protocol Popul ation 
Per-protocol (PP) population will include all subjects in the ITT population who do not have 
significant protocol deviations and who complete the 24 week visit . The rules for determining 
exclusions from the PP population will be finalized after a clinical review of the data and queries 
have been resolved but before unmasking treatment assignments. 
9.4.4 Pharmacokinetic Population  
Pharmacokinetic population will include all subjects in the pharmacokinetic portion of the study that provided blood samples for triamcinolone acetonide concentration analysis.  
9.5. Analysis Methods 
Efficacy and safety endpoints are provided in Section 3.1.  
9.5.1. Primary Efficacy Analysis  
The primary endpoint is the proportion of subjects with a change from baseline of ≥ 15 letters in 
ETDRS BCVA at Visit 8 (24 weeks), subsequent to suprachoroidal injections of CLS -TA or 
sham injection procedure s, in subjects with macular edema associated with  non-infectious 
uveitis.  
A Cochran-Mantel -Haenszel test will be used to test differences in the proportion of subjects in 
the two groups who show 15 or more letters improvement in BCVA at the week 24 visit after 
adjusting for center effects.  
The formal hypothesis is: 
H0: All OR site=1  H 1: OR site ≠1 
Where OR site is the odds ratio adjusting for site  
Missing d ata imputed by LOCF in the ITT population will be used for the primary efficacy 
analysis. Observed data in the PP population will be used for sensitivity analysis. See Section 
9.5.8 for a description of the imputations for missing data. 
9.5.2. Secondary Efficacy Analysis 
9.5.2.1. Secondary Efficacy Endpoint 
•Mean change from baseline in CST as measured by SD -OCT at 24 weeks (Visit 8)
9.5.2.2. Additional  Endpoints  
•Triamcinolone acetonide blood concentrations prior to each dose (Visit 2 and 5), 4weeks following the first dose (Visit 3) and at 24 weeks (Visit 8)
•Change from baseline in subject reported outcomes as measured by the VisualFunction Questionnaire (VFQ-25) and EQ-5D questionnaire at 24 weeks
CLS1001- 301 Clinical Protocol  Clearside Biomedical, Inc.  
Version 4.0 12 April 2017  Page 43 of 65 
CONFIDENTIAL  9.5.3. Subgr oup Analysis 
No subgroup analyses are planned. 
9.5.4. Pharmacokinetic Analysis 
Standard population PK parameters will be calculated from plasma CLS-TA concentrations. To 
characterize the population PK of CLS- TA, PK parameters will be related to treatment arm. 
Samples from approximately  20 subjects in the Active arm will be available for analysis. 
Analysis will be conducted according to the nonlinear mixed- effects approach and will provide 
estimates of population characteristics (intrinsic and extrinsic factors) that define the population distribution of the PK parameters. 
9.5.5. Safety Analysis  
9.5.5.1. Safety Endpoints  
• Incidence of treatment -emergent adverse events (TEAEs) and serious adverse events 
(SAEs), grouped by organ system, relatedness to study medication, and severity  
• Percentage of subj ects whose IOP increases  are > 10 mmHg  from their own baseline 
measurement at each follow -up visit (except Visit 2 & 5 [post-dose])  
• Percentage of subj ects whose IOP increases to a reading > 30 mmHg at each follow-up 
visit (except Visit 2 & 5 [post-dose]) 
• Percentage of subjects who require 1 or more additiona l IOP lowering medications at any 
follow-up visit (except Visit 2 & 5 [post-dose]) 
9.5.5.2. Intraocular Pressure  
The observed and change from baseline in IOP will be summarized descriptively at each visit.  
Descriptive statistics include n, mean, median, minimum and maximum values.   
9.5.5.3. Cataract Lens Grading 
The distribution of responses (n, %) will be tabulated for each category of response. 
9.5.5.4. Slit-Lamp Biomicroscopy  
The distribution of responses (n, %) will be tabulated for each category of response.  
9.5.5.5. Dilated Indirect  Ophthalmoscopy 
The distribution of responses (n, %) will be tabulated for each category of response. 9.5.5.6. Fluorescein Angiography 
FA will primarily be used to support SD-OCT analysis. In the event that grading occurs, t he 
distribution of responses (n, %) will be tabulated for each category of response.  
CLS1001- 301 Clinical Protocol  Clearside Biomedical, Inc.  
Version 4.0 12 April 2017  Page 44 of 65 
CONFIDENTIAL  9.5.5.7. Fundus Photographs  
Fundus photography will primarily be used to support SD-OCT analysis. In the event that 
grading occurs, t he distribution of responses (n, %) will be tabulated for each category of 
response. 
9.5.5.8. Clinical Laboratory Assessments and U rine Pregnancy T ests 
The observations for each analyte will be summarized descriptively  or tabulated categorically .  
Descriptive statistics include n, mean, median, minimum and maximum values.  
9.5.5.9. Review of Systems  
The proportion of subjects with abnormal body systems will be listed . 
9.5.5.10. Vital Signs  
The observations and change from baseline in vital signs will be summarized descriptively at 
each visit.  Descriptive statistics include n, mean, median, minimum and maximum valu es.   
9.5.5.11. Adverse Events  
AEs will be coded using the Medical Dictionary for Regulatory Activities ( MedDRA ) coding 
dictionary.  TEAEs wi ll be defined as any event occurring post treatment (injection) or, if pre-
existing, worsening after Day 1.   
The incidence o f TEAEs will be summarized by MedDRA system organ class and preferred 
term.  If the subject reports the same AE more than once, then that subject will only be counted 
once for the summary of that AE, using the most severe intensity and closest relationship to 
study treatment. 
TEAEs will be summarized as follows:  
• All TEAEs  
• All TEAEs by intensity  
• ALL TEAEs related to study drug 
• Treatment -emergent SAEs  
• TEAEs that lead to premature d iscontinuation of study drug   
• If few AE are reported, AEs wil l only be provide d in a listing  
9.5.5.12. Prior and Concomitant Medications 
Prior and concomitant medications taken from 30 days (3 years for significant ophthalmi c 
medications) prior to Visit 1 (Screening) through the duration of the subjects’ participation in the 
study will be summarized.   
9.5.6. Interim Analysis  
There is no interim analysis planned for this study.   
CLS1001- 301 Clinical Protocol  Clearside Biomedical, Inc.  
Version 4.0 12 April 2017  Page 45 of 65 
CONFIDENTIAL  9.5.7. Extent of Exposure 
The extent of exposure (i.e., whether a subject received the injection and whether it was a 
complete or partial injection) will be listed.  
9.5.8. Procedure for Accounting for Missing, Unused, or Spurious Data  
Any missing, unused, or spurious data will be noted in the final clinical  report. 
Last Observation Carried  Forward (LOCF) will be used if visits are missed in the ITT 
population.  No imputation for missed visits will be used in the PP population.  This provides an 
indication of the sensitivity of the data to missing observations.   
Likewise, LOCF will be used if a subject requires rescue medication . All data points will be set 
to missing following a subject’s receipt of a rescue medication; the last recorded data prior to the 
rescue will be carried forward to all subsequent visits for ITT. No imputation for rescue 
mediations will be used in the  PP population.  
No imputation is pla nned for the safety data set.  
9.5.9. Multiplicity  
Since there is only one primary endpoint, no multiplicity adjustments are required for the primary analysis.  
9.5.10. Procedure for Reporting Deviations from the Statistical Analysis Plan  
The statistical analysis plan will be completed prior to breaking treatment code.  
Any deviations from the statistical analysis plan will be described and a justification given in the final clinical study report.  
CLS1001- 301 Clinical Protocol  Clearside Biomedical, Inc.  
Version 4.0 12 April 2017  Page 46 of 65 
CONFIDENTIAL  10. DIRECT ACCESS TO SOURCE DATA/DOCUMENTS  
The I nvestigator will permit trial-related monitoring, audits, IRB /IEC  review, and regulatory 
inspection(s) by providing direct access of source data and documents (such as tests performed 
as a requirement for participation in the study and other medical record s required to confirm 
information contained in the CRF  such as medical history).  In addition, the I nvestigator will 
permit members of the s ponsor company to witness and record (video and/or audio) subject  
injections if the subject agrees in writing by pro viding informed consent and appropriate HIPAA 
authorization.  
10.1. Investigator Training  
The injecting physicians  will be trained by the Sponsor on study drug injection and training will 
be documented.  Only trained Investigators may adm inister study drug .  Investigators and key 
support staff will be trained by the Sponsor regarding all aspects of this protocol.  In addition, 
sites will be trained to perform imaging ( SD-OCT , FA and fundus photos) per the protocol so 
that the data may be uploaded to a Central Reading Center .  Only trained and certified visual 
acuity technicians may measure BCVA on study subjects using certified exam lanes.   
It is the responsibility of the Investigator to train ancillary study staff  if needed. 
10.2. Monitoring  
This study will be monitored in accordance with GCP and regulatory guidelines.  By signing this protocol, the investigator agrees to periodic, on- site monitoring of all appropriate study 
documentation. 
The progress of the study will be monitored by periodic on- site visits and  frequent 
communications between the Sponsor (or designee) and the Investigator (either by phone, fax, 
email, or post). 
During these contacts, the monitor will: c heck and assess the progress of the study ; review study 
data collected ; conduct source documen t verification; identify any issu es and address their 
resolution. The objectives of monitoring procedures are to verify that data are authentic, accurate, and 
complete; that the safety and rights of subjects are being protected; and that the study is conducted in accordance with the currently approved protocol (and any amendments), GCP, and all applicable regulatory requirements.  
10.3. Audits  
At its discretion, the Sponsor may conduct a quality assurance audit of this study.  If such an 
audit occurs, the I nvestigator agrees to allow the auditor direct access to all relevant documents 
and to schedule his/her time and the time of his/her staff to permit meetings with the auditor to discuss findings and any relevant issues. 
In addition, regulatory agencies may conduct a regulatory inspection of this study.  If such an 
inspection occurs, the investigator agrees to allow the inspector direct access to all relevant 
documents and to schedule his/her time and the time of his/her staff to permit meetings with the 
auditor to discuss findings and any relevant issues. 
CLS1001- 301 Clinical Protocol  Clearside Biomedical, Inc.  
Version 4.0 12 April 2017  Page 47 of 65 
CONFIDENTIAL  11. QUALITY CONTROL  AND QUALITY ASSURANCE  
The progress of the study will be monitored by onsite, written, e- mail, and telephone 
communications between personnel at the study center and the Sponsor .  The  Investi gator will 
allow Sponsor monitors, or designee(s) to inspect all CRFs , subject  records (source documents),  
signed informed consent forms, records of study medication receipt, storage, and disposition, and 
regulatory files related to the study.  
At the time of database lock, the clinical database will be audited in order to ensure accuracy of 
the data,  as well as to provide an estimated error rate for the final, locked database.  The audit 
will involve a comparison of CRF values with values from data listings generated from the clinical database.  Values identified as critical safety and efficacy variables will be confirmed for 100% of the subjects.  In addition, a random sample of subjects will be selected for which all 
data values, excluding comment fields, will be checked.  The number of subjects whose data will 
be randomly reviewed will be determined in order to provide sufficient accuracy for the estimated error rate of the clinical database.  
CLS1001- 301 Clinical Protocol  Clearside Biomedical, Inc.  
Version 4.0 12 April 2017  Page 48 of 65 
CONFIDENTIAL  12. ETHICS 
12.1. Institutional Review Board/Ethics Committee  
This protocol, the informed consent document, relevant supporting information, and all types of 
subject recruitment or advertisement information must be approved by the appropriate IRB/IEC 
before the study is initiated.  Any amendments to the protocol must also be approved, where 
necessary, by the IRB /IEC  prior to implementing changes in the study.  Documentation of these 
approvals must be provided to the sponsor prior to the initiation of the amendment.  The IRB/IEC used must comply with current GCP and guidelines. 
The investigator’s responsibilities regarding the IRB /IEC  are as follows:  
• Obtain IRB/IEC approval of the protocol, informed consent, and any advertisements to 
recruit subjects prior to their use  
• Obtain IRB/IEC approval for any protocol amendments and informed consent revisions before implementing the changes  
• Provide the IRB/IEC with any required information before and during the study.   
• Submit progress reports to the IRB/IEC, as required, during the conduct of the study; request re -review and approval of the study, as needed; provide copies of all IRB/IEC re-
approvals and relevant communication to the sponsor 
• Notify the IRB/IEC within 10 days of all serious and unexpected AEs related to the study medications that are reported to you by the sponsor.  The investigator is responsible for updating the IRB/IEC on the progress of the study and of any changes made to the 
protocol as deemed appropriate, but (in any case) at least once a year.  The investigator 
must also keep the IRB/IEC informed of any AEs, according to the IRB/IEC policy. 
12.2. Unanticipated Problems and Notification to Sponsor  and IRB/ IEC 
The I nvestigator will be responsible for notifying the Sponsor within 24 hours of awareness and 
the IRB/IEC within 10 days of all unanticipated problems involving risk to subjects or others.   
The regulations state that for studies conducted under 21 CFR part 312, investigators must report all "unanticipated problems" to the IRB [§§ 312.66, 312.53(c)(1)(vii), and 56.108(b)(1)]. 
As noted in FDA’s Gu idance on Adverse Event Reporting to IRBs – Improving Human Subject 
Protection (Jan 2009), the following AEs should be considered as unanticipated problems that 
must be reported to the IRB.  
• A single occurrence of a serious, unexpected event that is uncommon and strongly associated with drug exposure (such as angioedema, agranulocytosis, hepatic injury, or Stevens-Johnson syndrome) 
• A single occurrence, or more often a small number of occurrences, of a serious, unexpected event that is not commonly associated with drug exposure, but uncommon in the study population (eg, tendon rupture, progressive multifocal leukoencephalopathy) 
CLS1001- 301 Clinical Protocol Clearside Biomedical, Inc.  
Version 4.0 12 April 2017  Page 49 of 65 
CONFIDENTIAL  •Multiple occurrences of an AE that, based on an aggregate analysis, is determined to  
be an unanticipated problem.  There should be a determination that t he series of AEs 
represents a signal that the AEs were not just isolated occurrences and involve risk to 
human subjects (e.g., a comparison of rates across treatment groups reveals higher 
rate in the d rug treatment arm versus a control).
•An AE that is described or addressed in the investigator’s 
brochure, protocol, or 
informed consent documents, but occurs at a specificity or severity that is inconsistent  
with prior observations.  For example,
 if transaminase elevation is  listed in the 
investigator’s brochure and hepatic necrosis is 
observed in study subjects, hepatic  
necrosis would be considered an unanticipated problem involving risk to human  
subjects.
•A serious AE that is described or addressed in the investigator’s brochure, protocol,  or 
informed consent documents, but for which the rate of occurrence in the study 
represents a clinically significant increase i n the e xpected rate o f occurrence
•Any other AE or safety finding (e.g., based on animal or epidemiologic data) that 
would cause the sponsor to modify the investigator’s brochure, study protocol, or 
informed consent documents, or would prompt other action by the IRB to ensure the 
protection of human subjects 
12.3. Informed Consent Requirements  
The I nvestigator is responsible for obtaining written informed consent from each individual 
participating in this study after adequate explanation , in layman’s terms , regarding the nature of 
the study, along with the aims, methods, objectives, and any potential risks.  The informed 
consent document must be appropriately signed and dated by the subject or the subject’s legally 
authorized representative and the person obtaining the consent (if required by the IRB /IEC ) prior 
to conducting/obtaining any study-related assessments, including the discontinuation of any 
medications prohibited for the study. 
If the informed consent document is amended during the study, the investigator must follow all 
applicable regulatory requirements pertaining to approval of the amended informed consent by the IRB /IEC and use of the amended form (including for ongoing subjects).  
The informed consent document shall also contain the subject's authorization for the use and disclosure of his/her protected health information (PHI) in connection with the study.  The authorization shall include at a minimum a clear description of the following:  the duration of the 
authorization, the subject's right of access to the PHI (or any suspension thereof during the 
course of the study), type of information to be used/disclosed in t he study, the names or classes 
of parties that may use or disclose the PHI, the purpose of the use/disclosure of PHI, the extent of 
the subject's right to revoke the authorization, the extent to which participation in the study is 
conditioned on signing the authorization, and the potential for re-disclosure of PHI. 
Each informed consent will contain contact information with a phone number the subject should 
contact if they have medical concerns 24 hours a day. 
The original and any amended signed and dated informed consents must be retained at the study 
site. A copy must be given to the subject or subject’s legally authorized representative(s). 
CLS1001- 301 Clinical Protocol  Clearside Biomedical, Inc.  
Version 4.0 12 April 2017  Page 50 of 65 
CONFIDENTIAL  13. DATA HANDLING AND RE CORD KEEPING 
Study data will be processed and managed for clinical data management according to ICH 
Guidelines and US Food and Drug Administration regulations for the handling and analysis of 
data for clinical trials.  Clinical study data will be captured in CRFs by study personnel at the 
clinical sites .  CRFs will be monitored on a routine basis, with comparisons made to the various 
source documents maintained at the study sites.   
13.1. Data Quality Control and Reporting  
13.1.1. Source Documents  
Source documents consist of, but are not limited to, in-patient hospital charts, clinic notes, out-patient records, original test results, laboratory data, worksheets, drug accountability records, consent forms, etc.  Source documents must be available for review and inspection during on- site 
monitoring of the study by the Sponsor, their designees, IRB, and/or regulatory authorities. 
It is required that the author of an entry in the source documents be identifiable. Direct access to 
source documentation must be allowed for the purpose of verifying that the data recorded on the eCRF are consistent with the original source data.  
13.1.2. Case Report Forms  
Source documentation for data collected in this study will be maintained at the investigative site.  In cases where no source will be used, it will be noted in the investigator files.  Subject CRF data 
will be collected by EDC.  The EDC system will be Part 11 compliant and will have documented 
audit trail for all changes made to the CRF.  Data in the EDC system will be  periodically 
monitored for accuracy. 
The investigator or designee must record all required subject data using the previously specified 
data collection method defined by Clearside.  The investigator must sign and date a declaration on the CRF attesting to his/her responsibility for the quality of all data recorded and that the data 
represents a complete and accurate record of each subject's participation in the study.  
ECRF data will be provided to the investigator at the end of the study and will need to be retained by the investigator.   
13.1.3. Subject Tracking  
A site drug accountability log, subject drug accountability logs, a subject identification log (to be retained by the I nvestigator only), and a subject screening/enrollment log may be used to track 
subject participation in the study.   In addition, subject  randomization assignments will be tracked 
in an electronic IWRS system.   
13.1.4. Study Files  
Each investigational center will maintain a special study file.  This file is subject to monitoring and inspection as de scribed under Section 10.2 and Section 10.3 of this protocol.  This file may 
contain, but is not limited to, the following: 
• Protocol and protocol amendments 
CLS1001- 301 Clinical Protocol Clearside Biomedical, Inc.  
Version 4.0 12 April 2017  Page 51 of 65 
CONFIDENTIAL  •Safety reports that were submitted to regulatory authorities
•Investigator’ s Brochure
•IRB/IEC approva ls
•IRB/IEC approved informed consent and authorization form
•IRB/IEC (or privacy board) waiver of authorization (if applicable)
•Investigational center notice of privacy
 practices (if ap plicable)
•IRB/IEC correspondence
•IRB/IEC membership list
•Study Communications/Correspondence (letters, memos, meeting notes, 
faxes, and
printed emails)
•Signed Form FDA 1572 with corresponding curriculum vitae of Principal Investigator
and listed Sub-Investigator(s)
•Site signature log
•Delegation of authority log
•Drug accountability records (receipt, dispensing, return or destruction)
•Laboratory normal ranges and certification
•Laboratory director’s curriculum vitae
•SAE Reports (as applicable)
•Subject identification 
log
•Informed consent log
•Investigator(s) financial disclosure statement
13.2. Archiving of Data 
The clinical database will be archived at Clearside  and at the contract research organization  
responsible for data management for an agreed upon timeframe, if applicable.  
13.3. Records Retention  
The participating clinical center will retain all records related to the study in accordance with 
local and ICH GCP guidelines. 
CLS1001- 301 Clinical Protocol  Clearside Biomedical, Inc.  
Version 4.0 12 April 2017  Page 52 of 65 
CONFIDENTIAL  14. FINANCING AND INSURANCE  
14.1. Finance  
This study is supported by Clearside  Biomedical, Inc.  
14.2. Insurance  
Documentation of product liability i nsurance is on file at Clearside Biomedical, Inc. and is 
available upon request.  
CLS1001- 301 Clinical Protocol  Clearside Biomedical, Inc.  
Version 4.0 12 April 2017  Page 53 of 65 
CONFIDENTIAL  15. PUBLICATION POLICY 
The institution and investigators participating in this trial shall have no right to publish or present 
the results of this study without the prior written consent of the Sponsor. 
CLS1001- 301 Clinical Protocol  Clearside Biomedical, Inc.  
Version 4.0 12 April 2017  Page 54 of 65 
CONFIDENTIAL  16. REFERENCES  
Bodaghi B, Cassoux N, Bertrand W, et al. Chronic severe uveitis: etiology and visual outcome in 
927 patients from a single center. Medicine. 2001;80:263-270. 
Cho H, Madu A. Etiology and treatment of the inflammatory causes of cystoid macular edema. J 
Inflamm Res . 2009;2:37-43. 
Dick AD. The treatment of chronic uveitic macular edema. Br J Ophthalmol. 1994;78:1-2. 
Ghate D, Brooks W, McCarey BE, Edelhauser HF. Pharmacokinetics of intraocular drug 
delivery by periocular injections using ocular fluorophotometry. Invest Ophthalmol Vis Sci. 2007;48:2230-7. 
Goldstein DA, Pyatetsky D, Tessler HH.  Classification, symptoms, and signs of uveitis.  
Duane’s Ophthalmology on DVD-ROM Ed 2009a:chap 32. 
Jabs DA, Rosenbaum JT,  Foster CS, et al. Guidelines for the use of immunosuppressive drugs in 
patients with ocular inflammatory disorder s: recommendations of an expert panel. Am J 
Ophthalmol. 2000;130:492-513. 
Karim R, Sykakis E, Lightman S, Fraser-Bell S. Interventions for the treatment of uveitic 
macular edema: a systematic review and meta-analysis. Clin Opthalmol. 2013;7:1109-1144. 
Lard enoye C, Kooji B, Rothova A. Impact of macular edema on visual acuity in uveitis. 
Ophthalmology 2006;113:1446-1449. 
Lowder C, Belfort R, Lightman S, et al . Dexamethasone Intravitreal Implant for Noninfectious 
Intermediate or Posterior Uveitis. Arch Ophthalmol. 2011;129(5):545-553. Miserocchi E, Fogliato G, Modorati G and Bandello F. Review on the worldwide epidemiology 
of uveitis. Eur J Ophthalmol. 2013;23:705-717. 
Nussenblatt RB, Palestine AG, Chan CC, Roberge F. Standardization of vitreal inflammatory 
activity in intermediate and posterior uveitis. Ophthalmology. 1985;92(4):467– 471. 
Rothova A, Suttorp-van Schulten SA, Treffers WF and Kijlstra A. Causes and frequency of 
blindness in patients with intraocular inflammatory disease. Br J Ophalmol. 1996;80:332-336. 
SUN Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results from the first international workshop. Am J Ophthalmol 2005;150:509-516. 
Triesence [Package Insert]. Fort Worth, Texas: Alcon Laboratories, Inc., 2007. 
Wood B. An overview of uveitis and its management. US Pharmacist 2011. 
CLS1001- 301 Clinical Protocol  Clearside Biomedical, Inc.  
Version 4.0 12 April 2017  Page 55 of 65 
CONFIDENTIAL  17. APPENDICES  
 
 
   
CLS1001- 301 Clinical Protocol  Clearside Biomedical, Inc.  
Version 4.0 12 April 2017  Page 56 of 65 
CONFIDENTIAL  APPENDIX A.  TIME  AND EVENTS SCHEDULE  
Visit #  Visit 1  Visit 2  Visit 3  Visit 4  Visit 5  Visit 6  Visit 7  Visit 8  
Visit Type  Screening  Randomization 
/Treatment #1  Follow -Up Treatment #2  Follow -Up End Of 
Study  
Visit Window  Day  
-14 to -1 Day 0 Month 1  
Week 4  
Day 28 ± 5  Month 2  
Week 8  
Day 56 ± 5  Month 3  
Week 12  
Day 84 ± 5  Month 4  
Week 16  
Day 112  
± 5 Month 5  
Week 20  
Day 140  
± 5 Month 6  
Week 24  
Day 168  
± 5 
Assessments   Pre-dose  Post-dose   Pre-dose  Post-dose    
Informed Consent  √          
Assign Subject Number  √          
Demographics, Medical & Ocular Hx  √          
Eligibility Criteria  √ √         
Assess AEs  √ √ √ √ √ √ √ √ √ √ 
Con Med Review  √ √ √ √ √ √ √ √ √ √ 
Resting HR & BP  √ √    √    √ 
Central Lab Tests1 √         √ 
Review of Systems  √         √ 
BCVA4 √ √  √ √ √  √ √ √ 
Slit lamp Biomicroscopy2, 4 √ √ √ √ √ √ √ √ √ √ 
IOP5 √ √ √ √ √ √ √ √ √ √ 
Dilated Indirect  Ophthalmoscopy4 √ √ √ √ √ √ √ √ √ √ 
SD-OCT4 √ √  √ √ √  √ √ √ 
CLS1001- 301 Clinical Protocol  Clearside Biomedical, Inc.  
Version 4.0 12 April 2017  Page 57 of 65 
CONFIDENTIAL  Visit #  Visit 1  Visit 2  Visit 3  Visit 4  Visit 5  Visit 6  Visit 7  Visit 8  
Visit Type  Screening  Randomization 
/Treatment #1  Follow -Up Treatment #2  Follow -Up End Of 
Study  
Visit Window  Day  
-14 to -1 Day 0 Month 1  
Week 4  
Day 28 ± 5  Month 2  
Week 8  
Day 56 ± 5  Month 3  
Week 12  
Day 84 ± 5  Month 4  
Week 16  
Day 112  
± 5 Month 5  
Week 20  
Day 140  
± 5 Month 6  
Week 24  
Day 168  
± 5 
Assessments   Pre-dose  Post-dose   Pre-dose  Post-dose    
VFQ -25 & EQ -5D  √        √ 
PK Blood Draw ( optional )   √  √  √    √ 
Select Study Eye/Confirm Study Eye  √     √     
Fluorescein Angiogram4 √         √ 
Fundus Photos4 √         √ 
IWRS/Randomize   √    √     
Study Drug Treatment3   
       
1. Central lab test samples should be collected prior to FA being performed; central labs include a serum pregnancy test for females of child bearing potential 
2. Any finding of cataract should be graded  
3. Injection should be administered the same day as the pre- injection assessments at Visit 2 and at Visit 5  
4. Completed for both eyes at Visit 1 and Visit 8; study eye only for all other visits  
5. IOP collected for both eyes, except post -injection when data is collected for s tudy eye only  
  INJECT3 INJECT3 
CLS1001- 301 Clinical Protocol  Clearside Biomedical, Inc.  
Version 4.0 12 April 2017  Page 58 of 65 
CONFIDENTIAL  APPENDIX B.  SUMMARY OF CHANGES FOR AMENDMENTS  
CLS1001- 301 Clinical Protocol  Clearside Biomedical, Inc.  
Version 4.0 12 April 2017  Page 59 of 65 
CONFIDENTIAL  Amendment 1      
Section Changed  Initial Protocol  
(Changed From)  Modified Protocol  
(Changed To)  Reason for Change  Impact on Subjects 
(Risk/Benefit)  
List of Abbreviations   EQ-5D: European Quality of Life 5 -
Dimensions  
 To Add an  abbreviation and 
its associated definition  None  
Section 4.2.1. Ophthalmic  
Exclusion Criteria  #5. History of any vitreoretinal 
surgery (scleral buckle, pars plana 
vitrectomy, retrieval of a dropped 
nucleus or intraocular lens , etc. ; 
prior photocoagulation and IVT 
injections are acceptable) 
 #5. History of any vitreoretinal 
surgery ( examples include but are 
not limited to scleral buckle, pars 
plana vitrectomy, retrieval of a 
dropped nucleus or intraocular lens;  
prior photocoagulation and IVT 
injections are acceptable) 
 To clarify that the surgeries 
provided are a partial list of potential excluded surgeries  None  
Section 4.2.2. General  
Exclusion Criteria  #20. Has taken any 
interferon/fingolimod or any other 
drug in the 6 weeks prior to Visit 2, 
where the drug is known to induce 
macular edema  
 #20. Has taken any fingolimod or 
any other drug in the 6 weeks prior 
to Visit 2, where the drug is known 
to induce macular edema  
 Interferon has been 
removed from this criter ia 
as it is not known to induce 
macular edema  None  
Section 5.1.7.  Visit 5 – 
Week 12 – TREATMENT 
VISIT 2  The randomization code and kit 
number initially assigned to a 
subject will remain the same 
throughout the study.  The randomization arm initially 
assigned to a subject will remain the 
same throughout the study.  To clarify that a new kit 
number will be assigned at 
Visit 5  None  
Section 5.1.7.2.  Injection 
Procedure and Immediate  
Post-Injection Assessments  
 
 
 Retrieve study drug kit number assigned by  IRT AT VISIT 2  
 Retrieve study drug kit number assigned by IRT  To clarify that a  new kit 
number will be assigned at 
Visit 5  None  
CLS1001- 301 Clinical Protocol  Clearside Biomedical, Inc.  
Version 4.0 12 April 2017  Page 60 of 65 
CONFIDENTIAL  Amendment 1      
Section Changed  Initial Protocol  
(Changed From)  Modified Protocol  
(Changed To)  Reason for Change  Impact on Subjects 
(Risk/Benefit)  
Section 6.2.1. Prohibited 
Medications  
 Interferon / f ingolimod or any other 
drug known to induce ME  
 Fingolimod or any other drug known 
to induce ME  
 Interferon has been removed from this list as it 
is not known to induce 
macular edema  
  
Section 6.2.2. Additional  
Treatment   In the investigator’s medical judgement, the uveitic complications 
in the study eye have not improved and the condition needs to be 
addressed  
 To clarify that additional 
therapy may be 
implemented, at the Investigator’s discretion, for 
those subjects whose uveitis 
symptoms are not 
improving  Investigator’s d iscretion 
may be used to treat  
subject s who are not 
improving.  
Section 6.5.  
Masking/Unmasking  
  
 
  
 
 If masking is compromised, any 
personnel unmasked will not 
conduct any further masked clinical evaluations with the unmasked 
subject. Both  the masked or unmasked 
Investigator and staff may 
participate in evaluations conducted 
during the screening visit.  
 If masking is compromised, any masked personnel who become 
unmasked will not conduct any 
further masked clinical evaluations with the subject whose treatment has 
been unmasked.  
 To clarify which staff/inve stigators may 
conduct evaluations during 
the screening visit  
  To clarify who is eligible to 
conduct clinical evaluations 
following an unmasking event  None  
   
 
 None  
Section 8.2.2. Cataract  
Lens Grading  
  
 Graders must verify training on the 
grading procedure.  Graders must verify training on the grading procedure  provided in the 
Manual of Procedures. 
 To clarify where the 
cataract grading procedure 
is located  None  
CLS1001- 301 Clinical Protocol  Clearside Biomedical, Inc.  
Version 4.0 12 April 2017  Page 61 of 65 
CONFIDENTIAL  Amendment 1      
Section Changed  Initial Protocol  
(Changed From)  Modified Protocol  
(Changed To)  Reason for Change  Impact on Subjects 
(Risk/Benefit)  
Section 8.7. Clinical 
Laboratory Tests; Table 4 Urinalysis: Bilirubin; blood; 
glucose; ketone; protein; specific gravity; urobilinogen and  pH 
 Urinalysis: Bilirubin; blood; 
glucose; ketone; protein; specific gravity; pH  To remove urobilinogen from the analytes to be tested; bilirubin is a 
satisfactory measure of potential clinical problems  
 None  
Throughout protocol  Miscellaneous typographical and formatting errors   
  To correct typographical 
and formatting errors   None  
Amendment 2     
Section Changed  
 
 Previous  Protocol  
(Changed From)  Modified Protocol  
(Changed To)  Reason for Change  Impact on Subjects 
(Risk/Benefit)  
Throughout protocol  
 Miscellaneous typographical and 
formatting errors   To correct typographical 
and formatting errors  None  
  
CLS1001- 301 Clinical Protocol  Clearside Biomedical, Inc.  
Version 4.0 12 April 2017  Page 62 of 65 
CONFIDENTIAL  Amendment 2     
Section Changed  Previous  Protocol  
(Changed From)  Modified Protocol  
(Changed To)  Reason for Change  Impact on Subjects 
(Risk/Benefit)  
Section 4.2.1 Ophthalmic  
Exclusion Criteria, 
Criterion # 5  History of any vitreoretinal surgery (examples include but are not limited to scleral buckle, pars plana 
vitrectomy, retrieval of a dropped 
nucleus or intraocular lens; prior photocoagulation and IVT 
injections are acceptable) in the 
study eye; prior cataract extraction or Yttrium -Aluminum -Garnet laser 
capsulotomy is allowed, but must have been performed at least 3 months prior to Visit 2  History of any vitreoretinal surgery (examples include but are not limited to scleral buckle, retrieval of 
a dropped nucleus or intraocular 
lens; (prior photocoagulation and 
IVT injections are acceptable) in the 
study eye; prior cataract extraction, 
Yttrium -Aluminum -Garnet laser 
capsulotomy , and pars plana 
vitrectomy  is allowed, but must have 
been performed at least 3 months 
prior to Visit 2  To incl ude pars plana 
vitrectomy as an allowed vitreoretinal surgery if 
conducted at least 3 months 
prior to subject randomization .  3 months is 
sufficient to allow healing; altered clearance from the vitreous is not a concern 
with this method of 
delivery.   None  
Amendment 3     
Section Changed  
 
 Previous  Protocol  
(Changed From)  Modified Protocol  
(Changed To)  Reason for Change  Impact on Subjects 
(Risk/Benefit)  
Title  page  1220 Old Alpharetta Rd., Suite 300  
Alpharetta, GA  30005  900 North Point Parkway, Suite 200  
Alpharetta, GA  30005  Clearside Biomedical, Inc. Address change  None  
Section 1.6. Population to 
be Studied  The study population includes approximately 150 adult subjects to 
be enrolled at approximately 50 
study sites.  The study population includes 
approximately 150 adult subjects to be enrolled at approximately 60 study sites.  To update the number of 
clinical sites participating 
on the study None  
  
CLS1001- 301 Clinical Protocol  Clearside Biomedical, Inc.  
Version 4.0 12 April 2017  Page 63 of 65 
CONFIDENTIAL  Amendment 3     
Section Changed  
 Previous Protocol  
(Changed From)  Modified Protocol  
(Changed To)  Reason for Change  Impact on Subjects 
(Risk/Benefit)  
Section 4.2.1 Ophthalmic  
Exclusion Criteria, 
Criterion # 1 7, 18, & 19  unless the dose has been stable for at least 2 weeks prior to Visit 2, and no change  in dosing is anticipated 
for the study duration  unless the dose has been stable for at least 2 weeks prior to Visit 2, and no increase in dosing is anticipated for 
the study duration; decreases and 
termination of dose are allowable during the study  To clarify that decreases in doses of systemic 
corticosteroid, 
immunomodulatory and 
NSAID  therapy are allowed 
during the study  None  
Section 5 . Procedures  & 
Appendix A  All ocular assessments at Visit 1 and Visit 8 will be performed on both eyes. Ocular assessments at all 
other visits (Visits 2 -7) will be 
performed on the study eye only.   
Perform ophthalmic assessments on 
the study eye only:  
1. ETDRS BCVA  
2. Slit-lamp biomicr oscopy  
3. IOP  
4. Dilated ophthalmoscopy  
5. SD-OCT and upload 
images to the Central Reading Center  
 All ocular assessments at Visit 1 and Visit 8 will be performed on both eyes. IOP will be collected in both 
eyes at all visits. All other o cular 
assessments at all other visits (Visits 
2-7) will be performed on the study 
eye only.   
Perform ophthalmic assessments on the study eye only, unless otherwise designated:  
6. ETDRS BCVA  
7. Slit-lamp biomicroscopy  
8. IOP (both eyes)  
9. Dilated ophthalmoscopy  
10. SD-OCT and upload 
images to the Central Reading Center  To collect IOP data on the fellow eye at all visits for comparison to the study eye 
IOP None  
CLS1001- 301 Clinical Protocol  Clearside Biomedical, Inc.  
Version 4.0 12 April 2017  Page 64 of 65 
CONFIDENTIAL  Amendment 3     
Section Changed  
 Previous Protocol  
(Changed From)  Modified Protocol  
(Changed To)  Reason for Change  Impact on Subjects 
(Risk/Benefit)  
Section 5. Procedures  Slit-lamp biomicroscopy  Slit-lamp biomicroscopy, including 
dilated lens grading  To clarify that dilated lens 
grading is to be conducted 
when a finding of cataract is 
noted during the slit lamp 
exam, consistent with the Time and Events Schedule (Appendix A)  None  
Section 6.2.1. Prohibited Medications  Use of the following medications are prohibited at any time during the study:  
• Changes  to topical 
ophthalmic NSAIDs in the study eye  
• Anti-angiogenic drugs 
(anti-VEGF) in the study 
eye or systemically (including pegaptanib sodium, bevac izumab, 
ranibizumab ) Use of the following medications are prohibited at any time during the study:  
• Increases to topical ophthalmic NSAIDs in the study eye  
• Anti-angiogenic drugs 
(anti-VEGF) in the study 
eye or systemically (including pegaptanib sodium, bevacizumab, ranibizumab, aflibercept)  To prohibit only increases in topical ophthalmic 
NSAIDs  
 
 
 
 To clarify that aflibercept is 
an additional example of an 
anti-VEGF medication  None  
 
 
  
 
 None  
 
CLS1001- 301 Clinical Protocol  Clearside Biomedical, Inc.  
Version 4.0 12 April 2017  Page 65 of 65 
CONFIDENTIAL  Amendment 3     
Section Changed  
 Previous Protocol  
(Changed From)  Modified Protocol  
(Changed To)  Reason for Change  Impact on Subjects 
(Risk/Benefit)  
Section 8.1. IOP  
Measurement  Intraocular pressure (IOP) will be 
measured by applanation 
tonometery (Goldmann or Tonopen) and results will be recorded in mmHg. A single 
measurement will be made at 
approximately the same time of day. The technician is encouraged to use the same tonometry method throughout the subject’s study participation. Tonometers must be 
calibrated for accuracy before the 
first subject screening at that site and according to the manufacturer specifications dur ing the study, 
until the last subject has exited the study at that site.  
 Intraocular pressure (IOP) will be 
measured by applanation tonometery and results will be recorded in mmHg. Where available, Goldmann applanation tonometry should be 
used at all visits. Tonopens may be 
used for post -injection pressure 
checks and in cases where no 
Goldmann is available. A single measurement will be made at approximately the same time of day. 
The technician is encouraged to use 
the same tonometry method for all pre-injection and non -injection 
measurements throughout the subject’s study participation. Tonometers must be calibrated for 
accuracy before the first subject 
screening at that site and according to the manufacturer specifications during the study, until the l ast 
subject has exited the study at that site.
 To collect higher quality 
IOP measurements by 
requiring that the more 
accurate applanation 
equipment is used at all 
visits  None  
 